Document:

Exhibit
10.1

 

GLUCOSE
BIOSENSOR SYSTEMS (GREATER CHINA) HOLDINGS, INC.

 

2019
Long Term Incentive Plan

 

Section
1. Purpose; Definitions.

 

1.1.
Purpose. The purpose of the Plan is to enable the Company to offer to employees, officers and directors of and consultants
to the Company and its Subsidiaries and Affiliates whose past, present and/or potential future contributions to the Company and
its Subsidiaries have been, are or will be important to the success of the Company, an opportunity to share monetarily in the
success of and/or acquire a proprietary interest in the Company. The various types of long-term incentive awards that may be provided
under the Plan will enable the Company to respond to changes in compensation practices, tax laws, accounting regulations and the
size and diversity of its businesses.

 

1.2.
Definitions. For purposes of the Plan, the following terms shall be defined as set forth below:

 

(a)
“Affiliate” means a corporation, limited liability company or other entity that controls, is controlled by, or is
under common control with the Company and designated by the Committee from time to time as such.

 

(b)
“Agreement” means the agreement between the Company and the Holder, or such other document as may be determined by
the Committee, setting forth the terms and conditions of an award under the Plan.

 

(c)
“Asset Sale” means an acquisition by any one person, or more than one person acting as a group, together with acquisitions
during the 12-month period ending on the date of the most recent acquisition by such person or persons, of assets from the Company
that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets
of the Company immediately before such acquisition or acquisitions. For this purpose, gross fair market value means the value
of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated
with such assets.

 

(d)
“Board” means the Board of Directors of the Company.

 

(e)
“Change of Control” means a transaction in which any one person, or more than one person acting as a group, acquires
the ownership of stock of the Company that, together with the stock held by such person or group, constitutes more than 50% of
the total fair market value or combined voting power of the stock of the Company. A Change in Control caused by an increase in
the percentage of stock owned by any one person, or persons acting as a group, as a result of a transaction in which the Company
acquires its stock in exchange for property is not treated as a Change of Control for purposes of the Plan.

 

(f)
“Code” means the Internal Revenue Code of 1986, as amended from time to time.

 

(g)
“Committee” means the committee of the Board designated to administer the Plan as provided in Section 2.1. If no Committee
is so designated, then all references in this Plan to “Committee” shall mean the Board.

 

    	 	 	 

    	 

    

 

(h)
“Common Stock” means the Common Stock of the Company, par value $0.01 per share.

 

(i)
“Company” means Glucose Biosensor Systems (Greater China) Holdings, Inc., a corporation organized under the laws of
the State of Delaware.

 

(j)
“Disability” means physical or mental impairment as determined under procedures established by the Committee for purposes
of the Plan.

 

(k)
“Effective Date” means the date determined pursuant to Section 12.1.

 

(l)
“Fair Market Value,” unless otherwise required by any applicable provision of the Code or any regulations issued thereunder,
means, as of any given date: (i) if the Common Stock is listed on a national securities exchange or is traded over-the-counter
and last sale information is available, unless otherwise determined by the Committee, the last sale price of the Common Stock
in the principal trading market for the Common Stock on such date, as reported by the exchange or by such source that the Committee
deems reliable, as the case may be; or (ii) if the fair market value of the Common Stock cannot be determined pursuant to clause
(i), such price as the Committee shall determine, in good faith.

 

(m)
“Holder” means a person who has received an award under the Plan.

 

(n)
“Incentive Stock Option” means any Stock Option intended to be and designated as an “incentive stock option”
within the meaning of Section 422 of the Code.

 

(o)
“Non-qualified Stock Option” means any Stock Option that is not an Incentive Stock Option.

 

(p)
“Normal Retirement” means retirement from active employment with the Company or any Subsidiary on or after such age
which may be designated by the Committee as “retirement age” for any particular Holder. If no age is designated, it
shall be 65.

 

(q)
“Other Stock-Based Award” means an award under Section 8 that is valued in whole or in part by reference to, or is
otherwise based upon, Common Stock.

 

(r)
“Parent” means any present or future “parent corporation” of the Company, as such term is defined in Section
424(e) of the Code.

 

(s)
“Plan” means the Company’s 2019 Long Term Incentive Plan, as hereinafter amended from time to time.

 

(t)
“Repurchase Value” shall mean the Fair Market Value if the award to be settled under Section 2.2(e) or repurchased
under Section 5.2(l) is comprised of shares of Common Stock and the difference between Fair Market Value and the exercise price
(if lower than Fair Market Value) if the award is a Stock Option or Stock Appreciation Right; in each case, multiplied by the
number of shares subject to the award. “Repurchase Value” if the award to be repurchased under Section 9.2 is comprised
of shares of Common Stock shall mean the greater of the Fair Market Value or the value of such award based upon the price per
share of Common Stock received or to be received by other shareholders of the Company in the event. “Repurchase Value”
if the award to be repurchased under Section 9.2 is comprised of Stock Options or Stock Appreciation Rights shall mean the difference
between the greater of (1) the Fair Market Value or the value of such award based upon the price per share of Common Stock received
or to be received by other shareholders of the Company in the event and (2) the exercise price (if lower), multiplied by the number
of shares subject to the award.

 

    	 	2	 

    	 

    

 

(u)
“Restriction Period” means the time or times within which awards may be subject to forfeiture, including upon termination
of employment or failure of performance conditions.

 

(v)
“Restricted Stock” means Common Stock received under an award made pursuant to Section 7 that is subject to restrictions
under Section 7.

 

(w)
“Restricted Stock Unit” means an unfunded, unsecured right to receive, on the applicable settlement date, one share
or an amount in cash or other consideration determined by the Committee to be of equal value as of such settlement date, subject
to certain vesting conditions and other restrictions.

 

(x)
“SAR Value” means the excess of the Fair Market Value (on the exercise date) over (a) the exercise price that the
participant would have otherwise had to pay to exercise the related Stock Option or (b) if a Stock Appreciation Right is granted
unrelated to a Stock Option, the Fair Market Value of a share of Common Stock on the date of grant of the Stock Appreciation Right,
in either case, multiplied by the number of shares for which the Stock Appreciation Right is exercised.

 

(y)
“Stock Appreciation Right” means the right to receive from the Company, without a cash payment to the Company, either
a number of shares of Common Stock equal to the SAR Value divided by the Fair Market Value (on the exercise date) or, at the Company’s
election, cash in the amount of the SAR Value.

 

(z)
“Stock Option” or “Option” means any option to purchase shares of Common Stock which is granted pursuant
to the Plan.

 

(aa)
“Subsidiary” means any present or future “subsidiary corporation” of the Company, as such term is defined
in Section 424(f) of the Code.

 

(bb)
“Vest” means to become exercisable or to otherwise obtain ownership rights in an award.

 

Section
2. Administration.

 

2.1.
Committee Membership. The Plan shall be administered by the Board or a Committee. If administered by a Committee, such
Committee shall be composed of at least two directors, all of whom are “non-employee” directors within the meaning
of Rule 16b-3 under the Securities Exchange Act of 1934, as amended. Committee members shall serve for such term as the Board
may in each case determine and shall be subject to removal at any time by the Board.

 

2.2.
Powers of Committee. The Committee shall have full authority to award, pursuant to the terms of the Plan: (i) Stock Options,
(ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Restricted Stock Units, and/or (v) Other Stock-Based Awards. For
purposes of illustration and not of limitation, the Committee shall have the authority (subject to the express provisions of this
Plan):

 

    	 	3	 

    	 

    

 

(a)
to select the officers, employees, directors and consultants of the Company or any Subsidiary to whom Stock Options, Stock Appreciation
Rights, Restricted Stock, Restricted Stock Units and/or Other Stock-Based Awards may from time to time be awarded hereunder;

 

(b)
to determine the terms and conditions, not inconsistent with the terms of the Plan, of any award granted hereunder (including,
but not limited to, number of shares, share exercise price or types of consideration paid upon exercise of such options, such
as other securities of the Company or other property, any restrictions or limitations, and any vesting, exchange, surrender, cancellation,
acceleration, termination, exercise or forfeiture provisions, as the Committee shall determine);

 

(c)
to determine any specified performance goals or such other factors or criteria which need to be attained for the vesting of an
award granted hereunder;

 

(d)
to determine the terms and conditions under which awards granted hereunder are to operate on a tandem basis and/or in conjunction
with or apart from other awards under this Plan and cash and non-cash awards made by the Company or any Subsidiary or Affiliate
outside of this Plan; and

 

(e)
to make payments and distributions with respect to awards (i.e., to “settle” awards) through cash payments
in an amount equal to the Repurchase Value.

 

The
Committee may not modify or amend any outstanding Option or Stock Appreciation Right to reduce the exercise price of such Option
or Stock Appreciation Right, as applicable, below the exercise price as of the date of grant of such Option or Stock Appreciation
Right. In addition, no payment of cash or other property having a value greater than the Repurchase Value may be made, and no
Option or Stock Appreciation Right with a lower exercise price may be granted, in exchange for, or in connection with, the cancellation
or surrender of an Option or Stock Appreciation Right.

 

Notwithstanding
anything to the contrary, the Committee shall not grant to any non-employee directors awards covering more than 20,000
shares of Common Stock in any year.

 

2.3.
Interpretation of Plan. Subject to Section 10, the Committee shall have the authority to adopt, alter and repeal such administrative
rules, guidelines and practices governing the Plan as it shall from time to time deem advisable, to interpret the terms and provisions
of the Plan and any award issued under the Plan (and to determine the form and substance of all Agreements relating thereto),
and to otherwise supervise the administration of the Plan. Subject to Section 11, all decisions made by the Committee pursuant
to the provisions of the Plan shall be made in the Committee’s sole discretion and shall be final and binding upon all persons,
including the Company and its Subsidiaries and Affiliates and the Holders.

 

    	 	4	 

    	 

    

 

Section
3. Stock Subject to Plan.

 

3.1.
Number of Shares. The total number of shares of Common Stock reserved and available for issuance under the Plan shall
be up to 500,000 shares. Shares of Common Stock under the Plan (“Shares”) may consist, in whole or in part, of authorized
and unissued shares or treasury shares. If any shares of Common Stock that have been granted pursuant to a Stock Option cease
to be subject to a Stock Option, or if any shares of Common Stock that are subject to any Stock Appreciation Right, Restricted
Stock award, Restricted Stock Units or Other Stock-Based Award granted hereunder are forfeited, or any such award otherwise terminates
without a payment being made to the Holder in the form of Common Stock, such shares shall again be available for distribution
in connection with future grants and awards under the Plan. Shares of Common Stock that are surrendered by a Holder or withheld
by the Company as full or partial payment in connection with any award under the Plan, as well as any shares of Common Stock surrendered
by a Holder or withheld by the Company or one of its Subsidiaries to satisfy the tax withholding obligations related to any award
under the Plan, shall not be available for subsequent awards under the Plan.

 

3.2.
Adjustment Upon Changes in Capitalization, Etc. In the event of any common stock dividend payable on shares of Common Stock,
Common Stock split or reverse split, combination or exchange of shares of Common Stock, or other extraordinary or unusual event
which results in a change in the shares of Common Stock of the Company as a whole, the Committee shall determine, in its sole
discretion, whether such change equitably requires an adjustment in the terms of any award in order to prevent dilution or enlargement
of the benefits available under the Plan (including number of shares subject to the award and the exercise price) or the aggregate
number of shares reserved for issuance under the Plan. Any such adjustments will be made by the Committee, whose determination
will be final, binding and conclusive.

 

3.3.
Administrative Stand Still. In the event of any changes in capitalization described above
in Section 3.2, or any other extraordinary transaction or change affecting the shares or the share price of Common Stock, including
any equity restructuring or any securities offering or other similar transaction, for administrative convenience, the Committee
may refuse to permit the exercise of any award for up to sixty days before and/or after such transaction; provided, however, that
the Committee may not refuse to permit the exercise of any award during the last five trading days prior to the expiration of
such award.

 

3.4.
Substitute Awards. In connection with an entity’s merger or consolidation with the Company or any Subsidiary or the
Company’s or any Subsidiary’s acquisition of an entity’s property or stock, the Committee may grant awards in
substitution for any options or other stock or stock-based awards granted before such merger or consolidation by such entity or
its affiliate. Substitute awards may be granted on such terms as the Committee deems appropriate, notwithstanding limitations
on awards in the Plan. Substitute awards will not count against the plan limit, except that shares acquired by exercise of substitute
Incentive Stock Options will count against the maximum number of shares that may be issued pursuant to the exercise of Incentive
Stock Options under the Plan.

 

Section
4. Eligibility.

 

Awards
may be made or granted to employees, officers, directors and consultants of the Company or its Subsidiaries who are deemed to
have rendered or to be able to render significant services to the Company or its Subsidiaries or Affiliates and who are deemed
to have contributed or to have the potential to contribute to the success of the Company and which recipients are qualified to
receive options under the regulations governing Form S-8 registration statements under the Securities Act of 1933, as amended
(“Securities Act”). No Incentive Stock Option shall be granted to any person who is not an employee of the Company
or its Parent or one of its Subsidiaries (including any non-employee directors) at the time of grant or so qualified as set forth
in the immediately preceding sentence. Notwithstanding anything to the contrary, an award may also be made or granted to a person
in connection with his hiring or retention, or at any time on or after the date he reaches an agreement (oral or written) with
the Company or its Subsidiaries or Parent with respect to such hiring or retention, even though it may be prior to the date the
person first performs services for the Company or its Subsidiaries; provided, however, that no portion of any such award shall
vest prior to the date the person first performs such services and the date of grant shall be deemed to be the date hiring or
retention commences.

 

    	 	5	 

    	 

    

 

Section
5. Stock Options.

 

5.1.
Grant and Exercise. Stock Options granted under the Plan may be of two types: (i) Incentive Stock Options and (ii) Non-qualified
Stock Options. Any Stock Option granted under the Plan shall contain such terms, not inconsistent with this Plan, or with respect
to Incentive Stock Options, not inconsistent with the Plan and the Code, as the Committee may from time to time approve. The Committee
shall have the authority to grant Incentive Stock Options or Non-qualified Stock Options, or both types of Stock Options which
may be granted alone or in addition to other awards granted under the Plan.

 

5.2.
Terms and Conditions. Stock Options granted under the Plan shall be subject to the following terms and conditions:

 

(a)
Option Term. The term of each Stock Option shall be fixed by the Committee; provided, however, that no Stock Option may
be exercisable after the expiration of ten years from the date of grant; provided, further, that no Incentive Stock Option granted
to a person who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of
voting stock of the Company (“10% Shareholder”) may be exercisable after the expiration of five years from the date
of grant.

 

(b)
Exercise Price. The exercise price per share of Common Stock purchasable under a Stock Option shall be determined by the
Committee at the time of grant; provided, however, that the exercise price of a Stock Option may not be less than 100% of the
Fair Market Value on the date of grant or, if greater, the par value of a share of Common Stock; provided, further, that the exercise
price of an Incentive Stock Option granted to a 10% Shareholder may not be less than 110% of the Fair Market Value on the date
of grant.

 

(c)
Exercisability. Stock Options shall be exercisable at such time or times and subject to such terms and conditions as shall
be determined by the Committee. The Committee intends generally to provide that Stock Options be exercisable only in installments,
i.e., that they vest over time, typically over a three-year period. The Committee may waive such installment exercise provisions
at any time at or after the time of grant in whole or in part, based upon such factors as the Committee determines.

 

(d)
Method of Exercise. Subject to whatever installment, exercise and waiting period provisions are applicable in a particular
case, Stock Options may be exercised in whole or in part at any time during the term of the Option by giving written notice of
exercise to the Company specifying the number of shares of Common Stock to be purchased. Such notice shall be accompanied by payment
in full of the purchase price, which shall be in cash or, if provided in the Agreement, either in shares of Common Stock (including
Restricted Stock and other contingent awards under this Plan) or partly in cash and partly in such Common Stock, or such other
means which the Committee determines are consistent with the Plan’s purpose and applicable law. Cash payments shall be made
by wire transfer, certified or bank check or personal check, in each case payable to the order of the Company; provided, however,
that the Company shall not be required to deliver certificates for shares of Common Stock with respect to which an Option is exercised
until the Company has confirmed the receipt of good and available funds in payment of the purchase price thereof (except that,
in the case of an exercise arrangement approved by the Committee and described in the next sentence of this section, payment may
be made as soon as practicable after the exercise). The Committee may permit a Holder to elect to pay the exercise price upon
the exercise of a Stock Option by irrevocably authorizing a third party to sell shares of Common Stock (or a sufficient portion
of the shares) acquired upon exercise of the Stock Option and remit to the Company a sufficient portion of the sale proceeds to
pay the entire exercise price and any tax withholding resulting from such exercise. The Committee may also authorize other means
for paying the exercise price of a Stock Option, including using the value of the Stock Option (as determined by the difference
in the Fair Market Value of the Common Stock and the exercise price of the Stock Option or other means determined by the Committee).

 

    	 	6	 

    	 

    

 

(e)
Stock Payments. Payments in the form of Common Stock shall be valued at the Fair Market Value on the date of exercise.
Such payments shall be made by delivery of stock certificates in negotiable form that are effective to transfer good and valid
title thereto to the Company, free of any liens or encumbrances.

 

(f)
Transferability. Except as may be set forth in the next sentence of this Section or in the Agreement, no Stock Option shall
be transferable by the Holder other than by will or by the laws of descent and distribution, and all Stock Options shall be exercisable,
during the Holder’s lifetime, only by the Holder (or, to the extent of legal incapacity or incompetency, the Holder’s
guardian or legal representative). Notwithstanding the foregoing, a Holder, with the approval of the Committee, may transfer a
Non-Qualified Stock Option (i) (A) by gift, for no consideration, or (B) pursuant to a domestic relations order, in either case,
to or for the benefit of the Holder’s “Immediate Family” (as defined below), or (ii) to an entity in which the
Holder and/or members of Holder’s Immediate Family own more than fifty percent of the voting interest, subject to such limits
as the Committee may establish and the execution of such documents as the Committee may require, and the transferee shall remain
subject to all the terms and conditions applicable to the Non-Qualified Stock Option prior to such transfer. The term “Immediate
Family” shall mean any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece,
nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law, including adoptive relationships,
any person sharing the Holder’s household (other than a tenant or employee), a trust in which these persons have more than
fifty percent beneficial interest, and a foundation in which these persons (or the Holder) control the management of the assets.
The Committee may, in its sole discretion, permit transfer of an Incentive Stock Option in a manner consistent with applicable
tax and securities law upon the Holder’s request.

 

(g)
Termination by Reason of Death. If a Holder’s employment by, or association with, the Company or its Subsidiary or
Affiliate terminates by reason of death, any Stock Option held by such Holder, unless otherwise determined by the Committee and
set forth in the Agreement, shall thereupon automatically terminate, except that the portion of such Stock Option that has vested
on the date of death may thereafter be exercised by the legal representative of the estate or by the legatee of the Holder under
the will of the Holder, for a period of one year (or such other greater or lesser period as the Committee may specify in the Agreement)
from the date of such death or until the expiration of the stated term of such Stock Option, whichever period is shorter.

 

    	 	7	 

    	 

    

 

(h)
Termination by Reason of Disability. If a Holder’s employment by, or association with, the Company or its Subsidiary
or Affiliate terminates by reason of Disability, any Stock Option held by such Holder, unless otherwise determined by the Committee
and set forth in the Agreement, shall thereupon automatically terminate, except that the portion of such Stock Option that has
vested on the date of termination may thereafter be exercised by the Holder for a period of one year (or such other greater or
lesser period as the Committee may specify in the Agreement) from the date of such termination or until the expiration of the
stated term of such Stock Option, whichever period is shorter.

 

(i)
Termination by Reason of Normal Retirement. Subject to the provisions of Section 12.3, if such Holder’s employment
by, or association with, the Company or its Subsidiary or Affiliate terminates due to Normal Retirement, any Stock Option held
by such Holder, unless otherwise determined by the Committee and set forth in the Agreement, shall thereupon automatically terminate,
except that the portion of such Stock Option that has vested on the date of termination may thereafter be exercised by the Holder
for a period of one year in the case of a Non-Qualified Stock Option or three months in the case of an Incentive Stock Option
(or such other greater or lesser period as the Committee may specify in the Agreement) from the date of such termination or until
the expiration of the stated term of such Stock Option, whichever period is shorter.

 

(j)
Other Termination. Subject to the provisions of Section 12.3, if such Holder’s employment by, or association with,
the Company or its Subsidiary or Affiliate terminates for any reason other than death, Disability or Normal Retirement, any Stock
Option held by such Holder, unless otherwise determined by the Committee and set forth in the Agreement, shall thereupon automatically
terminate, except that, if the Holder’s employment is terminated by the Company or its Subsidiary or Affiliate without cause,
the portion of such Stock Option that has vested on the date of termination may thereafter be exercised by the Holder for a period
of three months (or such other greater or lesser period as the Committee may specify in the Agreement) from the date of such termination
or until the expiration of the stated term of such Stock Option, whichever period is shorter.

 

(k)
Incentive Stock Options. The aggregate Fair Market Value (on the date of grant of the Stock Option) of shares of Common
Stock with respect to which Incentive Stock Options become exercisable for the first time by a Holder during any calendar year
(under all such plans of the Company and its Subsidiaries and Affiliates) shall not exceed $100,000. To the extent that any Stock
Option intended to qualify as an Incentive Stock Option does not so qualify, including by reason of the immediately preceding
sentence, it shall constitute a separate Non-qualified Stock Option. The Company shall have no liability to any Holder or any
other person if a Stock Option designated as an Incentive Stock Option fails to qualify as such at any time or if a Stock Option
is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code and
the terms of such Stock Option do not satisfy the requirements of Section 409A of the Code.

 

(l)
Buyout and Settlement Provisions. The Committee may at any time, in its sole discretion, offer to repurchase a Stock Option
previously granted, at a purchase price not to exceed the Repurchase Value, based upon such terms and conditions as the Committee
shall establish and communicate to the Holder at the time that such offer is made.

 

(m)
Rights as Shareholder. A Holder shall have none of the rights of a Shareholder with respect to the shares subject to the
Option until such shares shall be transferred to the Holder upon the exercise of the Option.

 

    	 	8	 

    	 

    

 

Section
6. Stock Appreciation Rights.

 

6.1.
Grant and Exercise. Subject to the terms and conditions of the Plan, the Committee may grant Stock Appreciation Rights
in tandem with an Option or alone and unrelated to an Option. The Committee may grant Stock Appreciation Rights to participants
who have been or are being granted Stock Options under the Plan as a means of allowing such participants to exercise their Stock
Options without the need to pay the exercise price in cash. In the case of a Non-qualified Stock Option, a Stock Appreciation
Right may be granted either at or after the time of the grant of such Non-qualified Stock Option. In the case of an Incentive
Stock Option, a Stock Appreciation Right may be granted only at the time of the grant of such Incentive Stock Option.

 

6.2.
Terms and Conditions. Stock Appreciation Rights shall be subject to the following terms and conditions:

 

(a)
Exercisability. Stock Appreciation Rights shall be exercisable as shall be determined by the Committee and set forth in
the Agreement, subject, for Stock Appreciation Rights granted in tandem with an Incentive Stock Option, to the limitations, if
any, imposed by the Code with respect to related Incentive Stock Options.

 

(b)
Termination. All or a portion of a Stock Appreciation Right granted in tandem with a Stock Option shall terminate and shall
no longer be exercisable upon the termination or after the exercise of the applicable portion of the related Stock Option.

 

(c)
Method of Exercise. Stock Appreciation Rights shall be exercisable upon such terms and conditions as shall be determined
by the Committee and set forth in the Agreement and, for Stock Appreciation Rights granted in tandem with a Stock Option, by surrendering
the applicable portion of the related Stock Option. Upon exercise of all or a portion of a Stock Appreciation Right and, if applicable,
surrender of the applicable portion of the related Stock Option, the Holder shall be entitled to receive a number of shares of
Common Stock equal to the SAR Value divided by the Fair Market Value on the date the Stock Appreciation Right is exercised or,
at the Company’s election, cash for the value so calculated.

 

(d)
Shares Available Under Plan. The granting of a Stock Appreciation Right in tandem with a Stock Option shall not affect
the number of shares of Common Stock available for awards under the Plan. The number of shares available for awards under the
Plan will, however, be reduced by the number of shares of Common Stock acquirable upon exercise of the Stock Option to which such
Stock Appreciation Right relates.

 

Section
7. Restricted Stock; Restricted Stock Units.

 

7.1.
Grant. The Committee may award shares of Restricted Stock. In addition, the Committee may award Restricted Stock Units.
The Committee shall determine the eligible persons to whom, and the time or times at which, grants of Restricted Stock or Restricted
Stock Units will be awarded, the number of shares to be awarded, the price (if any) to be paid by the Holder, any Restriction
Period, the vesting schedule and rights to acceleration thereof, and all other terms and conditions of the awards.

 

7.2.
Restricted Stock Terms and Conditions. Each Restricted Stock award shall be subject to the following terms and conditions:

 

    	 	9	 

    	 

    

 

(a)
Certificates. Restricted Stock, when issued, will be represented by a stock certificate or certificates registered in the
name of the Holder to whom such Restricted Stock shall have been awarded. During the Restriction Period, certificates representing
the Restricted Stock and any securities constituting Retained Distributions (as defined below) shall bear a legend to the effect
that ownership of the Restricted Stock (and such Retained Distributions) and the enjoyment of all rights appurtenant thereto are
subject to the restrictions, terms and conditions provided in the Plan and the Agreement. Such certificates shall be deposited
by the Holder with the Company, together with stock powers or other instruments of assignment, each endorsed in blank, which will
permit transfer to the Company of all or any portion of the Restricted Stock and any securities constituting Retained Distributions
that shall be forfeited or that shall not become vested in accordance with the Plan and the Agreement.

 

(b)
Rights of Holder. Restricted Stock shall constitute issued and outstanding shares of Common Stock for all corporate purposes.
The Holder will have the right to vote such Restricted Stock and to exercise all other rights, powers and privileges of a holder
of Common Stock with respect to such Restricted Stock, with the exceptions that (i) the Holder will not be entitled to delivery
of the stock certificate or certificates representing such Restricted Stock until the Restriction Period shall have expired and
unless all other vesting requirements with respect thereto shall have been fulfilled; (ii) the Company will retain custody of
the stock certificate or certificates representing the Restricted Stock during the Restriction Period; (iii) the Company will
retain custody of all dividends and distributions (“Retained Distributions”) made, paid or declared with respect to
the Restricted Stock (and such Retained Distributions will be subject to the same restrictions, terms and conditions as are applicable
to the Restricted Stock) until such time, if ever, as the Restricted Stock with respect to which such Retained Distributions shall
have been made, paid or declared shall have become vested and with respect to which the Restriction Period shall have expired;
and (iv) a breach by the Holder of any of the restrictions, terms or conditions contained in this Plan or the Agreement or otherwise
established by the Committee with respect to any Restricted Stock or Retained Distributions will cause a forfeiture of such Restricted
Stock and any Retained Distributions with respect thereto.

 

(c)
Vesting; Forfeiture. Upon the expiration of the Restriction Period with respect to each award of Restricted Stock and the
satisfaction of any other applicable restrictions, terms and conditions, (i) all or part of such Restricted Stock shall become
vested in accordance with the terms of the Agreement, and (ii) any Retained Distributions with respect to such Restricted Stock
shall become vested to the extent that the Restricted Stock related thereto shall have become vested. Any such Restricted Stock
and Retained Distributions that do not vest shall be forfeited to the Company and the Holder shall not thereafter have any rights
with respect to such Restricted Stock and Retained Distributions that shall have been so forfeited.

 

7.3.
Restricted Stock Units Terms and Conditions. Each Restricted Stock Units award shall be subject to the following terms
and conditions:

 

(a)
Settlement. The Committee may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably
practicable after the Restriction Period with respect to the award of the Restricted Stock Units and the satisfaction of any other
applicable restrictions, terms and conditions, or will instead be deferred, on a mandatory basis or at the Holder’s election,
in a manner intended to comply with Section 409A.

 

    	 	10	 

    	 

    

 

(b)
Stockholder Rights. A Holder will have no rights of a holder of Common Stock with respect to shares subject to any Restricted
Stock Unit unless and until the shares are delivered in settlement of the Restricted Stock Unit.

 

(c)
Dividend Equivalents. If the Committee provides, a grant of Restricted Stock Units may provide a Holder with the right
to receive dividend equivalents. Dividend equivalents may be paid currently or credited to an account for the Holder, settled
in cash or shares and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with
respect to which the dividend equivalents are granted and subject to other terms and conditions as set forth in the Agreement.

 

Section
8. Other Stock-Based Awards.

 

Other
Stock-Based Awards may be awarded, subject to limitations under applicable law, that are denominated or payable in, valued in
whole or in part by reference to, or otherwise based on or related to, shares of Common Stock, as deemed by the Committee to be
consistent with the purposes of the Plan, including, without limitation, purchase rights, shares of Common Stock awarded which
are not subject to any restrictions or conditions, convertible or exchangeable debentures, or other rights convertible into shares
of Common Stock and awards valued by reference to the value of securities of or the performance of specified Subsidiaries. These
Other Stock-Based Awards may include performance shares or options, whose award is tied to specific performance goals. Other Stock-Based
Awards may be awarded either alone or in addition to or in tandem with any other awards under this Plan or any other plan of the
Company. Each Other Stock-Based Award shall be subject to such terms and conditions as may be determined by the Committee.

 

Section
9. Accelerated Vesting and Exercisability.

 

9.1.
Non-Approved Transactions. If there is a Change of Control that has not been approved by the Company’s Board of Directors,
then the vesting periods of any and all Stock Options and other awards granted and outstanding under the Plan shall be accelerated
and all such Stock Options and awards will immediately and entirely vest, and the respective holders thereof will have the immediate
right to purchase and/or receive any and all Common Stock subject to such Stock Options and awards on the terms set forth in this
Plan and the respective Agreements respecting such Stock Options and awards, and all performance goals will be deemed achieved
at 100% of target levels and all other terms and conditions will be deemed met.

 

9.2.
Approved Transactions. In the event of an Asset Sale, or if there is a Change of Control that has been approved by the
Company’s Board of Directors, then the Committee may (i) accelerate the vesting of any and all Stock Options and other awards
granted and outstanding under the Plan; (ii) require a Holder of any Stock Option, Stock Appreciation Right, Restricted Stock
award or Other Stock-Based Award granted under this Plan to relinquish such award to the Company upon the tender by the Company
to Holder of cash, stock or other property, or any combination thereof, in an amount equal to the Repurchase Value of such award;
provided, however, that the obligation to tender the Repurchase Value to such Holders may be subject to any terms
and conditions to which the tender of consideration to the Company’s stockholders in connection with the acquisition is
subject, including any terms and conditions of the acquisition providing for an adjustment to or escrow of such consideration;
and provided, further, that in the case of any Stock Option or Stock Appreciation Right with an exercise price that equals or
exceeds the price paid for a share of Common Stock in connection with the acquisition, the Committee may cancel the Stock Option
or Stock Appreciation Right without the payment of consideration therefor; and/or (iii) terminate all incomplete performance periods
in respect of awards in effect on the date the acquisition occurs, determine the extent to which performance goals have been met
based upon such information then available as it deems relevant and cause to be paid to the Holder the all or the applicable portion
of the award based upon the Committee’s determination of the degree of attainment of performance goals, or on such other
basis determined by the Committee.

 

    	 	11	 

    	 

    

 

9.3.
Code Section 409A. Notwithstanding any provisions of this Plan or any award granted hereunder to the contrary, no acceleration
shall occur with respect to any award to the extent such acceleration would cause the Plan or an award granted hereunder to fail
to comply with Code Section 409A.

 

Section
10. Amendment and Termination.

 

The
Board may at any time, and from time to time, amend alter, suspend or discontinue any of the provisions of the Plan or any Agreement,
but no amendment, alteration, suspension or discontinuance shall be made that would impair the rights of a Holder under any Agreement
theretofore entered into hereunder, without the Holder’s consent, except as set forth in this Plan or the Agreement. Notwithstanding
anything to the contrary herein, no amendment to the provisions of the Plan shall be effective unless approved by the shareholders
of the Company to the extent shareholder approval is necessary to satisfy any provision of the Code or other applicable law or
the listing requirements of any national securities exchange on which the Company’s securities are listed.

 

Section
11. Term of Plan.

 

11.1.
Effective Date. The Effective Date of the Plan shall be the day immediately prior to the consummation of the Company’s
initial public offering pursuant to a registration statement declared effective by the SEC. The Plan has been approved by the
Company’s stockholders, consistent with applicable laws, simultaneously with the adoption of the Plan by the Company’s
Board.

 

11.2.
Termination Date.Unless terminated by the Board, this Plan shall continue to remain effective until such time as no further
awards may be granted and all awards granted under the Plan are no longer outstanding. Notwithstanding the foregoing, grants of
Incentive Stock Options may be made only during the ten-year period beginning on the Effective Date.

 

Section
12. General Provisions.

 

12.1.
Written Agreements. Each award granted under the Plan shall be confirmed by, and shall be subject to the terms of, the
Agreement executed by the Company and the Holder, or such other document as may be determined by the Committee. The Committee
may terminate any award made under the Plan if the Agreement relating thereto is not executed and returned to the Company within
10 days after the Agreement has been delivered to the Holder for his or her execution.

 

12.2.
Unfunded Status of Plan. The Plan is intended to constitute an “unfunded” plan for incentive and deferred compensation.
With respect to any payments not yet made to a Holder by the Company, nothing contained herein shall give any such Holder any
rights that are greater than those of a general creditor of the Company.

 

    	 	12	 

    	 

    

 

12.3.
Employees.

 

(a)
Engaging in Competition with the Company; Solicitation of Customers and Employees; Disclosure of Confidential Information.
If a Holder’s employment with the Company, a Subsidiary, Parent or Affiliate is terminated for any reason whatsoever, and
within 12 months after the date thereof such Holder either (i) accepts employment with any competitor of, or otherwise engages
in competition with, the Company, a Subsidiary, Parent or Affiliate, (ii) solicits any customers or employees of the Company,
a Subsidiary, Parent or Affiliate to do business with or render services to the Holder or any business with which the Holder becomes
affiliated or to which the Holder renders services or (iii) uses or discloses to anyone outside the Company any confidential information
of the Company, a Subsidiary, Parent or Affiliate in violation of the Company’s policies or any agreement between the Holder
and the Company, a Subsidiary, Parent or Affiliate, the Committee, in its sole discretion, may require such Holder to return to
the Company the economic value of any award that was realized or obtained by such Holder at any time during the period beginning
on the date that is six months prior to the date such Holder’s employment with the Company or its Subsidiary or Affiliate
is terminated; provided, however, that if the Holder is a resident of the State of California, such right must be exercised by
the Company for cash within six months after the date of termination of the Holder’s service to the Company or within six
months after exercise of the applicable Stock Option, whichever is later. In such event, Holder agrees to (1) remit to the Company,
in cash, an amount equal to the difference between the Fair Market Value of the shares on the date of termination (or the sales
price of such shares if the shares were sold during such six month period) and the price the Holder paid the Company for such
shares, or (2) in the case of SARs, return to the Company the full amount paid to the Holder in connection therewith.

 

(b)
Termination for Cause. If a Holder’s employment with the Company or its Subsidiary or Affiliate is terminated for
cause, the Committee may, in its sole discretion, require such Holder to return to the Company the economic value of any award
that was realized or obtained by such Holder at any time during the period beginning on that date that is six months prior to
the date such Holder’s employment with the Company is terminated. In such event, Holder agrees to (1) remit to the Company,
in cash, an amount equal to the difference between the Fair Market Value of the Shares on the date of termination (or the sales
price of such Shares if the Shares were sold during such six month period) and the price the Holder paid the Company for such
shares, (2) with the consent of the Company, which may be withheld for any reason or no reason, surrender to the Company shares
of Common Stock having a Fair Market Value equal to the Fair Market Value on the date they were acquired upon exercise of the
Option, or (3) in the case of SARs, return to the Company the full amount paid to the Holder in connection therewith.

 

(c)
No Right of Employment. Nothing contained in the Plan or in any award hereunder shall be deemed to confer upon any Holder
who is an employee of the Company, a Subsidiary, Parent or Affiliate any right to continued employment with the Company, a Subsidiary,
Parent or Affiliate, nor shall it interfere in any way with the right of the Company, a Subsidiary, Parent or Affiliate to terminate
the employment of any Holder who is an employee at any time.

 

12.4.
No Fractional Shares. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan. The Committee
shall determine whether cash, additional awards or other securities or property shall be issued or paid in lieu of fractional
shares of Common Stock or whether any fractional shares should be rounded, forfeited or otherwise eliminated.

 

    	 	13	 

    	 

    

 

12.5.
Provisions for Foreign Participants. The Committee may modify awards granted to Holders who are foreign nationals or employed
outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations
or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters.

 

12.6.
Limitations on Liability.

 

(a)
Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other employee or agent of the
Company, a Subsidiary, Parent or Affiliate will be liable to any Holder, former Holder, spouse, beneficiary, or any other person
for any claim, loss, liability, or expense incurred in connection with the Plan or any award, and such individual will not be
personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as member
of the Committee, director, officer, other employee or agent of the Company, a Subsidiary, Parent or Affiliate. The Company will
indemnify and hold harmless each director, officer, other employee and agent of the Company, a Subsidiary, Parent or Affiliate
that has been or will be granted or delegated any duty or power relating to the Plan’s administration or interpretation,
against any cost or expense (including attorneys’ fees) or liability (including any sum paid in settlement of a claim with
the Committee’s approval) arising from any act or omission concerning this Plan unless arising from such person’s
own fraud or bad faith. 

 

(b)
Neither the Company nor any Subsidiary or Affiliate shall be liable to a Holder or any other person as to: (i) the non-issuance
or sale of shares as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority
deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any shares hereunder; and (ii) any tax
consequence expected, but not realized, by any Holder or other person due to the receipt, exercise or settlement of any Award
granted hereunder.

 

12.7.
Lock-Up Period. The Company may, at the request of any underwriter or placement agent, in connection with the registered
offering of any Company securities under the Securities Act or pursuant to an exemption therefrom, prohibit Holders from, directly
or indirectly, selling or otherwise transferring any shares or other Company securities acquired under this Plan during a period
of up to one hundred eighty days following either the effective date of a Company registration statement filed under the Securities
Act, in the case of a registered offering, or the closing date of the sale of the Company securities, in the case of an offering
exempt from registration, or for such longer period as determined by the underwriter or placement agent.

 

    	 	14	 

    	 

    

 

12.8.
Data Privacy. As a condition for receiving any award, each Holder explicitly and unambiguously consents to the collection,
use and transfer, in electronic or other form, of personal data as described in this paragraph by and among the Company and any
Parent, Subsidiaries and Affiliates exclusively for implementing, administering and managing the Holder’s participation
in the Plan. The Company and any Parent, Subsidiaries and Affiliates may hold certain personal information about a Holder, including
the Holder’s name, address and telephone number; birthdate; social security, insurance number or other identification number;
salary; nationality; job title(s); any shares held in the Company or any Parent, Subsidiary or Affiliate; and award details, to
implement, manage and administer the Plan and awards (the “Data”). The Company and any Parent, Subsidiaries and Affiliates
may transfer the Data amongst themselves as necessary to implement, administer and manage a Holder’s participation in the
Plan, and the Company and any Parent, Subsidiaries and Affiliates may transfer the Data to third parties assisting the Company
with Plan implementation, administration and management. These recipients may be located in the Holder’s country, or elsewhere,
and the Holder’s country may have different data privacy laws and protections than the recipients’ country. By accepting
an award, each Holder authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other
form, to implement, administer and manage the Holder’s participation in the Plan, including any required Data transfer to
a broker or other third party with whom the Company or the Holder may elect to deposit any shares. The Data related to a Holder
will be held only as long as necessary to implement, administer, and manage the Holder’s participation in the Plan. A Holder
may, at any time, view the Data that the Company holds regarding such Holder, request additional information about the storage
and processing of the Data regarding such Holder, recommend any necessary corrections to the Data regarding the Holder or refuse
or withdraw the consents in this Section 12.8 in writing, without cost, by contacting the local human resources representative.
The Company may cancel Holder’s ability to participate in the Plan and, in the Committee’s discretion, the Holder
may forfeit any outstanding awards if the Holder refuses or withdraws the consents in this Section 12.8. For more information
on the consequences of refusing or withdrawing consent, Holders may contact their local human resources representative.

 

12.9.
Successor. The obligations of the Company under the Plan shall be binding upon any successor corporation or organization
resulting from the merger, consolidation or other reorganization of the Company, or upon any successor corporation or organization
succeeding to all or substantially all of the assets and business of the Company and its Subsidiaries, taken as a whole.

 

12.10.
Investment Representations; Company Policy. The Committee may require each person acquiring shares of Common Stock pursuant
to a Stock Option or other award under the Plan to represent to and agree with the Company in writing that the Holder is acquiring
the shares for investment without a view to distribution thereof. Each person acquiring shares of Common Stock pursuant to a Stock
Option or other award under the Plan shall be required to abide by all policies of the Company in effect at the time of such acquisition
and thereafter with respect to the ownership and trading of the Company’s securities.

 

12.11.
Additional Incentive Arrangements. Nothing contained in the Plan shall prevent the Board from adopting such other or additional
incentive arrangements as it may deem desirable, including, but not limited to, the granting of Stock Options and the awarding
of Common Stock and cash otherwise than under the Plan; and such arrangements may be either generally applicable or applicable
only in specific cases.

 

12.12.
Withholding Taxes. Not later than the date as of which an amount must first be included in the gross income of the Holder
for Federal income tax purposes with respect to any Stock Option or other award under the Plan, the Holder shall pay to the Company,
or make arrangements satisfactory to the Committee regarding the payment of, any Federal, state and local taxes of any kind required
by law to be withheld or paid with respect to such amount. If permitted by the Committee, tax withholding or payment obligations
may be settled with Common Stock, including Common Stock that is part of the award that gives rise to the withholding requirement.
The obligations of the Company under the Plan shall be conditioned upon such payment or arrangements and the Company or the Holder’s
employer (if not the Company) shall, to the extent permitted by law, have the right to deduct any such taxes from any payment
of any kind otherwise due to the Holder from the Company or any Subsidiary.

 

    	 	15	 

    	 

    

 

12.13.
Clawback. Notwithstanding any other provisions of the Plan, any award which is subject to recovery under any law, government
regulation or listing requirement of any national securities exchange on which the Company’s securities are listed, will
be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or listing
requirement (or any policy adopted by the Company pursuant to any such law, government regulation or listing requirement).

 

12.14.
Governing Law. The Plan and all awards made and actions taken thereunder shall be governed by and construed in accordance
with the law of the State of Delaware (without regard to choice of law provisions).

 

12.15.
Other Benefit Plans. Any award granted under the Plan shall not be deemed compensation for purposes of computing benefits
under any retirement plan of the Company or any Parent, Subsidiary or Affiliate and shall not affect any benefits under any other
benefit plan now or subsequently in effect under which the availability or amount of benefits is related to the level of compensation
(unless required by specific reference in any such other plan to awards under this Plan).

 

12.16.
Non-Transferability. Except as otherwise expressly provided in the Plan or the Agreement, no right or benefit under the
Plan may be alienated, sold, assigned, hypothecated, pledged, exchanged, transferred, encumbranced or charged, and any attempt
to alienate, sell, assign, hypothecate, pledge, exchange, transfer, encumber or charge the same shall be void.

 

12.17.
Applicable Laws. The obligations of the Company with respect to all Stock Options and other awards under the Plan shall
be subject to (i) all applicable laws, rules and regulations and such approvals by any governmental agencies as may be required,
including, without limitation, the Securities Act, and (ii) the rules and regulations of any securities exchange on which the
Common Stock may be listed. Notwithstanding anything herein to the contrary, the Plan and all awards will be administered only
in conformance with such applicable laws. To the extent such applicable laws permit, the Plan and all Agreements will be deemed
amended as necessary to conform to such applicable laws.

 

12.18.
Conflicts. If any of the terms or provisions of the Plan or an Agreement conflict with the requirements of Section 422
of the Code, then such terms or provisions shall be deemed inoperative to the extent they so conflict with such requirements.
Additionally, if this Plan or any Agreement does not contain any provision required to be included herein under Section 422 of
the Code, such provision shall be deemed to be incorporated herein and therein with the same force and effect as if such provision
had been set out at length herein and therein. If any of the terms or provisions of any Agreement conflict with any terms or provisions
of the Plan, then such terms or provisions shall be deemed inoperative to the extent they so conflict with the requirements of
the Plan. Additionally, if any Agreement does not contain any provision required to be included therein under the Plan, such provision
shall be deemed to be incorporated therein with the same force and effect as if such provision had been set out at length therein.

 

12.19.
Compliance with Section 409A of the Code. The Company intends that any awards be structured in compliance with, or to satisfy
an exemption from, Section 409A of the Code, such that there are no adverse tax consequences, interest, or penalties pursuant
to Section 409A of the Code as a result of the awards. Notwithstanding the Company’s intention, in the event any award is
subject to Section 409A of the Code, the Committee may, in its sole discretion and without a participant’s prior consent,
amend this Plan and/or outstanding Agreements, adopt policies and procedures, or take any other actions (including amendments,
policies, procedures and actions with retroactive effect) as are necessary or appropriate to (i) exempt this Plan and/or any award
from the application of Section 409A of the Code, (ii) preserve the intended tax treatment of any such award, or (iii) comply
with the requirements of Section 409A of the Code, including without limitation any such regulations guidance, compliance programs
and other interpretive authority that may be issued after the date of grant of an award. This Plan shall be interpreted at all
times in such a manner that the terms and provisions of the Plan and the awards are exempt from or comply with Section 409A of
the Code.

 

    	 	16	 

    	 

    

 

12.20.
Sub-Plans. The Committee may from time to time establish sub-plans under the Plan for purposes of satisfying blue sky,
securities, tax or other laws of various jurisdictions in which the Company intends to grant awards. Any sub-plans shall contain
such limitations and other terms and conditions as the Committee determines are necessary or desirable. All sub-plans shall be
deemed a part of the Plan, but each sub-plan shall apply only to the participants in the jurisdiction for which the sub-plan was
designed.

 

12.21.
Non-Registered Stock. The shares of Common Stock to be distributed under this Plan have not been, as of the Effective Date,
registered under the Securities Act or any applicable state or foreign securities laws and the Company has no obligation to any
Holder to register the Common Stock or to assist the Holder in obtaining an exemption from the various registration requirements,
or to list the Common Stock on a national securities exchange or any other trading or quotation system.

 

12.22.
Non-Uniform Treatment. The Committee’s determinations under the Plan need not be uniform and may be made by it selectively
among persons who are eligible to receive, or actually receive, awards. Without limiting the generality of the foregoing, the
Committee shall be entitled to make non-uniform and selective determinations, amendments and adjustments, and to enter into non-uniform
and selective Agreements.

 

    	 	17Exhibit
10.2

 

TECHNOLOGY
LICENSE AGREEMENT

 

This
Technology License Agreement (this “Agreement”) dated as of3rd July 2019 (the “Effective Date”),
is by and between the following parties:

 

Life
Science Biosensor Diagnostics Pty Ltd., an Australian proprietary limited company having an address at Level 9, 85 Castlereagh
Street, Sydney NSW 2000 Australia (“Licensor”); and

 

Glucose
Biosensor Systems (Greater China) Holdings Inc., a company having an address at 708 Third Avenue, 6th FloorNew York, New York
10017, (“Licensee”),

 

(each,
a “Party” and collectively the “Parties”).

 

WHEREAS:

 

	(a)	Licensor
    owns:

 

	 	i.	Technology
    related to measuring, or otherwise determining, the following: (a) the amount or concentration of glucose; (b) the existence
    of biological markers of cancer; and (c) allergy/ immunology and hormones, each in a bodily fluid (e.g., saliva, blood) (each
    an “Indicator” and collectively the “Indicators”);
	 	 	 
	 	ii.	products
    (including, meters, strips, and accessories), systems, methods, processes, applications, and implementation for or of measuring
    or otherwise determining the amount or concentration and existence of each Indicator in a bodily fluid (individually and collectively,
    the “Biosensor Technology”); and
	 	 	 
	 	iii.	Proprietary
    Rights in and to Biosensor Technology (individually and collectively, the “Biosensor Proprietary Rights,”
    collectively with the Biosensor Technology, the “Biosensor IP”).

 

	(b)	Licensor
    wishes to permit Licensee, and Licensee wishes to have the right, to use, manufacture, market, offer, and sell Licensed Products
    including using Biosensor Technology in accordance with the terms and conditions of this Agreement.

 

NOW,
THEREFORE, for good and valuable consideration, and intending to be legally bound, Parties agree as follows:

 

1.
Definitions; Interpretation

 

1.1
Definitions.

 

“Affiliate”
means any entity or other legal or juridical person that, directly or indirectly, controls, or is controlled by, or is under common
control with, Licensor; whereby “control” of a person or Party means direct or indirect ownership of fifty percent
(50%) or more of the beneficial or record ownership of the outstanding shares or other ownership interests or the direct or indirect
power to designate fifty percent (50%) or more of directors, managers, or individuals exercising authority in its governance;
provided that, notwithstanding the foregoing, Licensee shall be deemed not to be an Affiliate of Licensor under or in connection
with this Agreement.

 

“Anonymized
Database” means a database collecting all Anonymized Demographic Information, and all Biosensor Data provided by Licensor
to Licensee under Section 4.6, categorized under the different Anonymized Identifiers that is stored on a cloud-based server or
cloud based servers controlled by Licensor with a cloud server provider approved in advance in writing by Licensor to Licensee,
and any back-up database that may be continuously and simultaneously updated with such production database and is located geographically
separate from the production database, or any other server notified by Licensor to Licensee as the server for the purposes of
storing the production database.

 

    	 	1	 

     

    

 

“Anonymized
Demographic Information” means, with regard to an End User, all demographic information, including, without limitation,
gender, age, race or ethnicity, disease information, other medical information, and eponymous data, of such End User, but excluding
any End User Identifiable Data.

 

“Anonymized
End User Data” means collectively with regard to a specific Anonymized Identifier such Anonymized Identifier, all Anonymized
Demographic Information under such Anonymized Identifier, and all Biosensor Data under such Anonymized Identifier. The term Anonymized
End User Data does not include any End User Identifiable Data.

 

“Anonymized
Identifier” means a unique identifier given to an individual End User, which unique identifier has the only purpose
of distinguishing such individual End User from any other individual End User but does not disclose or make available to Licensor
the identity or any End User Data of such End User.

 

“Authorized
Supplier” means, with regard to a Licensed Product, Licensor, Licensee or any of their Affiliates, or any third party
manufacturer and/or reseller that: (a) Licensee has expressly identified or approved in advance in writing with the Licensor;
(b) can manufacture and supply the Licensed Product in accordance with Good Manufacturing Practices for the manufacture and supply
of such Licensed Product for the Licensee, provided that such a supplier shall cease being an Authorized Supplier upon the earlier
of Licensor’s notifying Licensee thereof in writing or that supplier not being able to manufacture and supply the Licensed
Product in accordance with Good Manufacturing Practices.

 

“Biosensor
Data” means, individually and collectively, any and all data, documentation, and information collected by any Licensed
Product that measures or otherwise determines the existence, amount or concentration of any one or more Indicator in a bodily
fluid (e.g., saliva, blood) and stores such values and other information and/or transmits such values and other information for
storage, viewing, or processing on a different instrument (including, the blood glucose level, date, time, and other information
from or related to a specific measurement).

 

“Biosensor
Data Destination” means a server outside the Territory as controlled by or for Licensor and as identified by Licensor
to Licensee from time to time.

 

“Commercial
Unit” means, with regard to a Licensed Product, one (1) biosensor strip product unit at which such Licensed Product
is offered by Licensee to, or resale or provision to, individual end users of such Licensed Product.

 

“Derivation”
means, with regard to any Technology, any modification, improvement, derivative work, derivation, adaptation, localization, translation,
transliteration, and/or compilation of any kind, directly or indirectly, to or of or from or based on or over such Technology.
A Derivation to any Technology that is a Derivation is also a Derivation.

 

“End
User” means, with regard to a Licensed Product, any individual who procures for use or uses any Commercial Unit of such
Licensed Product. For the avoidance of doubt, End User includes any subject who provides a bodily fluid for the assessment of
any one or more Indicator and performs such assessment using such provided bodily fluid and any individual who receives for the
assessment of any one or more Indicator a bodily fluid of another and performs such assessment using such received bodily fluid.

 

“End
User Identifiable Data” means, with regard to an End User, any data and information that relates to the past, present,
or future physical or mental health or condition of such End User; the provision of health care to such End User; or the past,
present, or future payment for the provision of health care to such End User; in each case that identifies such End User or with
respect to which there is a reasonable basis to believe such data and information can be used to identify such End User including,
without limitation, the name, address, social security or similar government-issued number, and number of a passport or other
government-issued identification document of such End User.

 

    	 	2	 

     

    

 

“End
User Identifiable Database” means a production database collecting all End User Identifiable Data that is stored on
a cloud-based server or cloud based servers with a cloud server provider approved in advance in writing by Licensor to Licensee
to which Licensee shall for the Term have continuous password-protected and secure access, and any back-up database that may be
continuously and simultaneously updated with such production database and is located geographically separate from the production
database, or any other server notified by Licensor to Licensee as the server for the purposes of storing the production database.

 

“Expiry
Date of the Patent” means the final date of the protection afforded to the patent portfolio directly associated with
the development of the Licensed Product, as advised in writing by Licensor to Licensee from time to time.

 

“Good
Manufacturing Practices” means the good manufacturing practices that apply to the manufacture of medical device and
therapeutic goods, including the Licensed Product, in the Territory and as required under any applicable law, including, but not
limited to, guidelines set by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human
Use (ICH)

 

“Interference”
means, with regard to a Database, any event of: (i) any Malware having any effect on any data in such Database, on any data while
transmitted to or from such Database, or on any access to, or ability to access, such Database or any data therein, and/or (ii)
any invasion into or unauthorized or fraudulent access to, or interference with, such Database, any data in such Database, or
any data while transmitted to or from such Database.

 

“IDE”
means an investigational device exemption that allows the Licensee to collect data for the purposes of supporting a pre-market
approval application to, or a premarket notification submission from, a Regulatory Authority so that it can manufacture, offer,
sell, promote and supply the Licensed Product within the Territory.

 

“Investigational
Device” means a device, including a transitional device, which is an embodiment of the Licensed Product for the purpose
of obtaining Regulatory Approval for the Licensed Product.

 

“Investigation”
means the process of conducting any clinical trial, investigation or research involving any one or more subject of the for the
purpose of obtaining Regulatory Approval for an Investigational Device.

 

“Licensed
Material” means any sales literature or other promotional documents, items, material, or things for use in connection
with promoting, marketing, offering for sale, manufacturing and selling Licensed Products made available, approved by the Licensor.

 

“Licensed
Product” means products relating to the Biosensor Technology as outlined in Schedule 1 which is developed by
an Authorized Supplier as outlined in Schedule 1.

 

“Licensed
Rights” means the right, to use, market, offer, and sell Licensed Products including the use of the Biosensor Technology
in the Territory under the Biosensor Proprietary Rights owned by Licensor with legal effect in the Territory, including, without
limitation, the Proprietary Rights set forth in Schedule 2.

 

“Licensed
Trademark” means any of the Marks set forth in Schedule 3, provided that: (i) if Licensor identifies use
of any such Mark only for a specific Licensed Product, such Mark is a Licensed Trademark only with regard to such Licensed Product;
and (ii) Licensor may at any time discontinue any such Mark as a Licensed Trademark, or replace any such Mark with a different
Mark, or modify any such Mark, or add a Mark as a Licensed Trademark, by written notice to Licensee, in which case, in accordance
with such written notice, such replaced or discontinued Mark shall cease to be a Licensed Trademark, such replacing or added Mark
shall become a Licensed Trademark, and such modified Mark shall be a Licensed Trademark only as so modified.

 

    	 	3	 

     

    

 

“Licensee
Personnel” means any officer, director, employee, agent, and contractor of Licensee, including, without limitation,
any distributor, or any direct or indirect subdistributor of any distributor, of Commercial Units under agreement with Licensee.

 

“Malware”
means, individually and collectively, any computer code or other mechanism of any kind designed to disrupt, disable or harm in
any manner the operation of any software or hardware or other business processes or to misuse, gain unauthorized access to or
misappropriate any business or personal information, including, without limitation, viruses, worms, Trojan horses, bombs, backdoors,
clocks, hidden keys, timers, traps or other disabling device code, or designs or routines that cause software or information to
be erased, inoperable or otherwise incapable of being used, either automatically or with passage of time or upon command.

 

“Mark”
means any trademark, service mark, trade name, corporate name, business name, domain name, design, logos, slogans, trade dress,
and other designation of source or origin, and any common law right, registration, application for registration, extension, and
renewal thereof or related thereto, and all goodwill of the business symbolized by any of the foregoing or associated therewith,
any where in or throughout the world and under any law or legal system.

 

“Net
sales” means the gross invoiced price for sales or other supplies of Licensed Products by the Licensee less only usual
arms’ length trade discounts and rebates actually given or allowed (such discounts and rebates not to exceed 5% of the gross
invoiced price), customs duties, transportation and insurance charges, and all taxes incurred on such sales.

 

“New
End User” means, with regard to any Licensed Product and with regard to a specified point in time, any End User who
has not previously, or has not during the preceding twelve (12) months’ time, procured such Licensed Product from Licensee
or any authorized distributor of Licensee.

 

“Royalty”
has the meaning set forth in Schedule 4.

 

“Projected
Net Sales” means a forecast for Net Sales on a rolling 5 year period, to be determined annually during the Term by agreement
in writing between the Licensor and the Licensee. In the event the Licensor and the Licensee cannot agree on the Projected Net
Sales in any year, the Projected Net Sales from the immediately preceding period will apply.

 

“Proprietary
Right” means any of the following, anywhere in or throughout the world and under any law or legal system: (i) any patent
and any patent application (including, without limitation, any utility and design patent and patent application, and any provisional,
continuation, continuation-in-part, divisional, reissue, reexamination, substitution, extension, and foreign, international and
other counterpart and equivalent of any patent and/or patent application), and any right in or to or arising from any utility
model, invention disclosure, patent disclosure, or invention (whether or not patentable), (ii) any copyright and any right similar
thereto, whether arising from statute, regulation, common or judicial law, treaty or otherwise, and any registration, application
for registration, and renewal thereof or related thereto, (iv) any mask work right, and any registration, application for registration,
and renewal thereof or related thereto, (v) any moral right, including, without limitation, rights of attribution and integrity,
(vi) any data base right and any right in or to or arising from any computer program (whether in source code, object code, or
other form), algorithm, data, website, webpage, web address, web presence, uniform resource locator, or digital property or information,
(vii) any right in or to or arising from any trade secret, any know-how, or any confidential information, (viii) any personality,
likeness, publicity, and privacy right, and (ix) any other intellectual or industrial property right, whether existing now or
being recognized or created in the future.

 

“Regulatory
Authority” means any: (a) government or governmental or semi-governmental authority; judicial entity; minister, department,
office, commission, delegate, instrumentality, agency, board, authority or organization of any government; regulatory organization
established under statute; or any standards organization administering or superintending compliance with standards within the
Territory, including, but not limited to, the National Medical Products Administration (formerly known as the China Food and Drug
Administration).

 

    	 	4	 

     

    

 

“Technology”
means, individually and collectively, any material, item, document, documentation, technology, invention, creation, development,
discovery, reduction to practice, design, process, method, equipment, practice, work, know-how, show-how, software, source code,
object code, other code, data, database, device, product, prototype, specification, application, implementation, conception, idea,
and information of any kind, whether tangible or intangible.

 

“Term”
means the period commencing on the Effective Date and continuing until the termination, expiration, or cancellation of this Agreement.

 

“Termination
Date” means the date this Agreement is terminated or cancelled in accordance with clause 8.

 

“Territory”
means each of the following (i) Mainland China; (ii) Hong Kong; (iii) Vietnam and (vi) Bangladesh.

 

1.2
Interpretation. In this Agreement: (i) any reference to “Section” means any of the numbered sections in this
Agreement; (ii) any reference to “Schedule” means any of the numbered schedules appended after the signature page
of this Agreement, which shall be deemed to be a part of this Agreement; (iii) any reference to any provision of a statute shall
be construed as a reference to that provision as amended, re-enacted or extended at the relevant time; (iv) where this Agreement
states that a Party “shall” or “will” perform in some manner or otherwise act or omit to act, it means
that such Party is legally obligated to do so in accordance with this Agreement; (v) the principle ejusdem generis shall
not apply to any provision in this Agreement; (vi) the provisions of this Agreement shall not be interpreted against the drafter,
and for purposes of any interpretation, both Parties shall be deemed to be drafters of this Agreement; (vii) all Section headings
and Schedule titles are intended solely for the convenience of the Parties, and none will be deemed to affect the meaning or construction
of any provision hereof; (viii) words of any gender used in this Agreement are intended to include any other gender, and words
in the singular number include the plural, and vice versa, unless the context clearly indicates otherwise; (ix) all amounts in
the agreement refer to amounts in United Sates of America dollars; (x) specifying anything in this Agreement after the words ‘include’
or ‘for example’ or similar expressions does not limit what else is included; and (xi) other parts of speech and grammatical
forms of a word or phrase defined in this Agreement have a corresponding meaning.

 

2.
Licenses

 

2.1 License.
Licensor hereby grants to Licensee a non-transferable, non-assignable, non- sublicensable, royalty-bearing and fee-bearing,
limited license during the Term, in accordance with the terms and conditions of this Agreement under (1) the Licensed Rights
and (2) Licensor’s ownership and legally enforceable rights in Biosensor, solely:

 

a.
to act as the regulatory authorisation holder for the purpose of, prosecuting the application of, and obtaining any, Regulatory
Approval, including, being authorized to carry out any one or more Investigation for the purpose of: (a) seeking approval from
the relevant Regulatory Authorities to prosecute any approval for an Investigational Device to be used by an End User; and (b)
applying for an IDE, including, obtaining approval for the Investigational Device to be shipped lawfully for the purpose of conducting
Investigations for that Investigational Device, with an objective to submit such Investigations to the Regulatory Authority for
Regulatory Approval.

 

b.
to promote, market, import into the Territory, manufacture (either as the, or through an, Authorized Supplier), offer, sell, and
supply Licensed Products in the Territory, solely for use in the Territory, and

 

c.
to provide reasonable customer support services to End Users of, and health care practitioners referring such End Users to use,
the Licensed Products in the Territory on the use of the Licensed Products,

 

    	 	5	 

     

    

 

d.
to use the Licensed Products only for the purposes identified and permitted pursuant to the regulatory approval obtained in the
Territory, and

 

e.
to collect for and on behalf of Licensor, Biosensor Data arising from use of Licensed Products in the Territory

 

(the
“License”). No other right or license is granted by Licensor under this Agreement in or to any Proprietary
Right or related to any Biosensor IP. Licensor has the right, but not the obligation, to agree to add or expand the License hereby
granted, including, but not limited to, by varying or adding to the Licensed Rights.

 

2.2
Exclusivity.

 

a.
The License is granted as an exclusive license in the Territory. Notwithstanding the exclusivity of the License under the foregoing
provision of this Section 2.2, nothing in this Agreement shall prevent or prohibit Licensor or any Affiliate from performing or
engaging in any direct or indirect promotion, marketing, import, export, representation, offer, sale, resale or supply outside
the Territory anywhere in any manner as decided by Licensor in its sole discretion, and Licensee shall have no right or claim
in connection therewith.

 

b.
The License does not permit, and the Licensee is prohibited from, exploiting or seeking to exploit any rights in respect of the
Licensed Product outside of the Territory through any means, including digitally or online, where the End User is not physically
resident in the Territory. The Licensee must do all things necessary in turn to ensure that any distributors of Licensed Products
in the Territory do not exploit or seek to exploit any rights in respect of the Licensed Product outside of the agreed territorial
boundaries for that particular distributor. For the avoidance of doubt a breach of the obligations set out in the clause will
be a material breach for the purposes of this agreement.

 

c.
The Licensor must (i) supply all Licensed Product as ordered by the Licensee in accordance with this agreement, (ii) ensure that
all Anonymized End User Data and End User Identifiable Data is accessible to the Licensee, and (iii) ensure that all Licensed
Product supplied to the Licensee will be of merchantable quality and in accordance with all laws and regulations in the Territory.

 

d.
Notwithstanding anything herein to the contrary, the License shall cease to be exclusive upon the latest Expiry Date of the Patents
covered by the License.

 

2.3
Trademark and Promotional Material License. Licensor hereby grants to Licensee a non- transferable, non-assignable, non-sublicensable,
limited license during the Term to use the Licensed Trademarks, and to reproduce, and use (without any modification or editing
not approved in advance in writing) any exact copies of any Licensed Material, solely in the Territory and solely for the purpose
of reasonably promoting, marketing, offering, selling the Licensed Products, all in accordance with the terms and conditions of
this Agreement (“Marketing License”). No other right or license is granted by Licensor under this Agreement
in or to any Licensed Trademark, any other Mark, or any Licensed Material. All use of the Licensed Trademarks shall comply with
any trademark usage guidelines that Licensor may provide to Licensee, as may be amended from time to time by Licensor in its sole
discretion with written notice to Licensee, and the provisions of this Section 2.3 and Section 2.4. Licensee shall ensure that
any Commercial Unit of a Licensed Product promoted and marketed under any Licensed Trademark, or with regard to which any Licensed
Trademark is used, meets the high quality of such Licensed Product made in accordance with Licensor’s specifications and
requirements and has not been modified, altered, or degraded in any way. Licensee shall not use any Licensed Trademark on or in
connection with any Commercial Unit that does not meet such quality requirements. Licensee may not use any Licensed Trademark
in any way such that it is used as, or appears to be, conjoined with any other mark or name without Licensor’s express prior
written consent and license and terms agreed to by Licensor in Licensor’s sole discretion. Licensee shall use each Licensed
Trademark at all times with such notice (® or TM as applicable) as directed by Licensor. Any Licensed Material shall
include a notice of Licensor’s copyrights by using the symbol ©, followed by the name of Licensor (or such other name
as identified by Licensor to Licensee) and the year identified by Licensor. Licensee may not modify, change, alter, cover, or
obliterate in any way any such marking or notice.

 

    	 	6	 

     

    

 

2.4 Limitations.
Licensee shall not assign or transfer, or grant any sublicense, or the right to sublicense, the license under this Agreement,
or agree or commit to do so, without the express consent of the Licensor in writing. Licensee does not have any license to,
and Licensee shall not: (i) use, practice, or reproduce any Biosensor Technology (other than as part of, and incidental to,
the marketing or promotion of any Licensed Product under the License), or use, make, promote, market, manufacture,
offer, sell, resell, represent, or license any product or service including or involving Biosensor Technology or Biosensor
Proprietary Rights other than the Licensed Products under the License; (ii) promote, market, import into the Territory,
manufacture, offer, sell, and supply Licensed Products outside, or for use or resale outside, the Territory or to the extent
Licensee knows or suspects that a third party buyer of Licensed Products will promote, market, export, offer, sell or supply
such Licensed Products outside or for use or application outside the Territory; (iii) promote, manufacture, market, offer,
sell, and supply Licensed Products for any use other than its intended use measuring or determining any one or more Indicator
in humans from saliva; (iv) not reverse engineer, decompile, disassemble, modify, edit, change, amend, customize, adapt, copy
or reproduce (except as and to the extent expressly permitted in the License), or create any Derivation of or to or from or
based on any Licensed Product or any Biosensor Technology; (v) without the prior written consent of Licensor include any
Licensed Product in, or combine any Licensed Product with, any product or any service other than a Licensed Product; (vi) use
any Licensed Trademark or any Licensed Material for any product or service other than a Licensed Product during the Term
under the Marketing License; (vii) use any Licensed Trademark or any Licensed Material outside the Territory; (viii) do or
omit to do anything that could adversely affect their validity or reputation or the reputation of Licensor or a Licensed
Product or a Licensed Trademark; and (ix) cause, induce, or permit any third party to do, or assist any third party with
doing, any of the foregoing, whether for the benefit of Licensee, such third party, and/or any other third party. Licensee
must immediately notify Licensor in writing if it becomes aware of a breach, or attempted breach, of any of the above
obligations.

 

2.4
A Sublicense. On request of the Licensee, the Licensor must in good faith consider a request to allow the Licensee to sub-license
its obligations under this Agreement to a third party. If provided, any consent will be subject to the Licensee retaining all
rights, obligations and liability under this Agreement.

 

2.5
Licensed Products. Licensor may require any change to any Licensed Product by any Authorized Supplier and may make any
change to any Licensed Material by Licensee, provided that such changes do not affect any Regulatory Approvals obtained by the
Licensee. As of the effective time of such change, Licensee shall promote, market, import into the Territory, offer, sell, manufacture
and supply such Licensed Product, and all Commercial Units thereof, consistent with such change, and use only Licensed Material
with such change. Licensor shall not be liable in any way to Licensee for any such change or any costs, expenses, damages, or
liability arising therefrom.

 

2.6
Infringements. Licensee shall give written notice to Licensor of any infringement or attempted infringement of any intellectual
property rights in or to any Licensed Material that comes to Licensee’s attention and shall cooperate reasonably with Licensor,
at Licensor’s reasonable and necessary expense and reasonable request, in preventing and stopping any such infringement.

 

2.7
Performance. Licensee shall:

 

a.
promote, market, manufacture, import, offer, sell, and supply the Licensed Products, and all Commercial Units, on an arm’s
length basis in accordance with all applicable law and the requirements set forth in Schedule 5;

 

b.
monitor and exercise all reasonable vigilance and meet all regulatory requirements in respect of quality control, sample control,
quality and control and any adverse events in respect of the Licensed Products; and

 

    	 	7	 

     

    

 

c.
Licensee shall be solely liable and responsible for all of its activities under this Agreement.

 

Without
limitation, Licensor shall not be liable for or obligated to make to Licensee, and Licensee shall not have any right or claim
against Licensor to, any fee, charge, compensation, reimbursement, or other payment of any kind in connection with any manufacturing,
making, installing, embedding, offering, selling, or other activity of Licensee.

 

2.8
Regulatory Approvals. Licensee shall file for, prosecute the application, and obtain the relevant regulatory approvals,
for each of the Licensed Products and all legal permits necessary for conducting clinical research, manufacturing, promoting,
marketing, offering, or selling each Licensed Product to the relevant regulatory authorities within the Territory, which will
include prosecuting the application for, and obtaining the relevant regulatory approvals for each Investigative Device referable
to each Licensed Product (“Regulatory Approval”). Licensor agrees to provide all information that is necessary
or advisable for obtaining the Regulatory Approval for each Licensed Product in each jurisdiction in the Territory.

 

3.
Fees and Royalties; Payment

 

3.1
Fees and Royalties. Licensee shall deliver to Licensor the reports, and pay to Licensor the Royalties (individually and
collectively, the “Compensation”) as set forth in Schedule 4.

 

3.2
Payment. Licensee shall pay all Compensation in readily available, indefeasible, unconditional funds, without any set-off
or deduction, in United States Dollar currency in such manner as directed by Licensor. Any amount of Compensation that is unpaid
when it is due shall accrue interest from the date it is due until Licensor’s receipt of the payment of such amount at the
rate of the lower of (i) one-and-one-half percent (1.5%) per each full or partial calendar month or (ii) the highest enforceable
rate of interest under applicable law. All such interest shall be paid simultaneously with the payment of the unpaid amount on
which such interest accrued.

 

3.3
Tax. Licensee shall bear or be liable or responsible for any sales, use, excise, value added, or other applicable taxes,
tariffs or duties, and none of which shall be included in or part of or deducted or withheld from any amount of any Compensation.
In the event that such taxes, tariffs or duties are assessed against Licensor, Licensee shall reimburse Licensor on demand for
any such amounts paid by Licensor. In the event that any such taxes, tariffs or duties are withheld from any payment to Licensor,
Licensee shall gross up the amount of such payment such that Licensor receives the full amount of such payment without any such
withholding.

 

3.4
Audit. Licensee will maintain financial records which are compliant with US generally accepted accounting principles (“GAAP”)
regarding all Compensation and data and information on which the calculation of Compensation in accordance with Schedule
4 is based for a period of not less than five (5) years after the end of the calendar year in which such Compensation
accrued. Licensor shall have the right, including through a certified public accountant, to audit and examine all such books and
records upon providing Licensee with reasonable notice. Licensee agrees to provide all reasonable assistance to Licensor and to
provide access to all personnel, employees and consultants and to premises at which books and records are retained for the purposes
of the audit referred to above, Licensor agrees to conduct any such audit during regular business hours. Any amount of Compensation
due but not paid shall be paid to Licensor immediately upon Licensee’s having notice of such non-payment. In the event that
an audit conducted by an auditor discloses, with regard to any type of Compensation, an underpayment of any amount of such type
of Compensation that is five percent (5%) or more of the full amount of such type of Compensation owed and due during the period
of time audited and examined, Licensee shall pay all reasonable and necessary costs and expenses of such audit and examination.
In the event that an audit has been conducted during the Term pursuant to which Licensee has become liable to pay all reasonable
and necessary costs of the audit, all reasonable and necessary costs and expenses of all future audits conducted by Licensor during
the Term will be at the cost of Licensee.

 

3.5
No Precedent. The Parties agree that the amount or rate of any Royalty or other Compensation is based on the particular
circumstances of this transaction, shall not be deemed to be a precedent for any other transaction, whether between the Parties
or of any third party, or in connection with any rights or remedies asserted by Licensor, and shall not be deemed to be an indication
of what constitutes or may constitute, or be used in the determination of, a maximum reasonable royalty regarding any patent or
other Proprietary Right of Licensor.

 

    	 	8	 

     

    

 

4.
Data

 

4.1
Anonymized End User Data. Licensee shall: (i) promptly upon adding an individual as a New End User, establish an Anonymized
Identifier for such End User, (ii) promptly obtain as much of the Anonymized Demographic Information of such End User as may be
lawfully and reasonably collected for such End User and record same under such Anonymized Identifier, (iii) continuously cause
all Biosensor Data for such End User to be automatically transmitted in real time under such Anonymized Identifier to the Biosensor
Data Destination, with Licensee intercepting, storing, or capturing (but not modifying) any Biosensor Data, and (iv) retain all
of the Anonymized Demographic Information of such End User and any shared Biosensor Data provided by Licensor to Licensee under
such Anonymized Identifier in a single cohesive database that is part of the Anonymized Database. Licensee shall ensure that all
Anonymized Demographic Information is at all times recorded, and all Biosensor Data are at all times transmitted, one-hundred
percent completely and accurately under the correct Anonymized Identifier. Licensee shall within five (5) calendar days after
each calendar month, and at all other times upon request of Licensor, deliver, or provide access to, any Anonymized Demographic
Information collected during such calendar month, all in compliance with applicable law and as otherwise requested by Licensor,
identified by the Anonymized Identifier therefor.

 

4.2
End User Identifiable Data. Licensee shall obtain an express consent from any End User (in writing or such other form as
required by applicable law and clearly provable in the event of any dispute) for the collection, processing, storage, transmission,
and disclosure of all End User Identifiable Data and all Anonymized End User Data of such End User, including specifically, without
limitation, all transmission thereof to, and the use under this Agreement, by Licensor of all Anonymized End User Data and, in
the event of Section 8.3(b), all End User Identifiable Data, of such End User. Licensee shall ensure that the Anonymized Database
at no time, and no Anonymized End User Data at any time, links or reference to any End User Identifiable Data or the End User
Identifiable Database, or vice versa. In no event shall Licensee disclose, provide, or provide or permit access to any
End User Identifiable Data of any End User to any third party other than to such End User except to the extent required by applicable
law or with the written consent of the End User.

 

4.3
Databases. Licensee shall, on behalf of Licensor, establish and continuously maintain the Anonymized Database and the End
User Identifiable Database (each, a “Database”) at its sole responsibility, cost, and expense. Licensee shall
establish each Database such that it is at all times secured against any Interference and maintained in accordance with all applicable
law, using state of the art and continuously updated firewalls anti-Malware software and tools, highly secured access, and other
measures as reasonable. In the event of any Interference, Licensee shall promptly determine and notify Licensor of any impact
of such Interference, and perform any notification and other actions as required by applicable law. Licensee shall at all times
keep the Anonymized Database and the End User Identifiable Database completely digitally and physically separate without any links
or cross-references between both. Licensee shall ensure that no Anonymized End User Data or Anonymized Identifier is stored or
introduced into the End User Identifiable Database, and that no End User Identifiable Data is stored or introduced into the Anonymized
Database.

 

4.4
Correlation Database. Licensee shall create and maintain a list, cross-references or other correlation of End Users or
End User Identifiable Data with any Anonymized End User Data allowing the correlation of each End User’s End User Identifiable
Data with the Anonymized End User Data collected from such End User (the “Correlation Database”), provided
that the Correlation Database shall be maintained solely in a secure data base and server that is digitally and physically remote
from the Databases and the servers including either of the Databases. Licensee shall establish the Correlation Database such that
it is at all times secured against any Interference and maintained in accordance with all applicable law, using state of the art
and continuously updated firewalls anti-Malware software and tools, highly secured access, and other measures as reasonable. In
the event of any Interference, Licensee shall promptly determine and notify Licensor of any impact of such Interference, and perform
any notification and other actions as required by applicable law. In the event of any adverse event related to a Licensed Product
or its use (including, without limitation, a defect in a Licensed Product or a health or safety issue arising from its use) (“Adverse
Event”), Licensee shall promptly notify Licensor of such Adverse Event and resolve such Adverse Event in collaboration
and coordination with Licensor, including, without limitation, through use of the Correlation Database as necessary. Licensor
shall have the right to access the Correlation Database and the information thereon if it is necessary to address a serious Adverse
Event or if required or permitted by court order or governmental order in connection with an Adverse Event.

 

    	 	9	 

     

    

 

4.5
Ownership. Notwithstanding, and without limiting, the obligations and liability of Licensee for all Anonymized Data and
the Anonymized Database as set forth in this Agreement, all Anonymized End User Data, and the Anonymized Database, shall be belong
to, and be solely owned by, Licensor from the time of their creation. Licensee hereby assigns, transfers, and conveys any and
all rights, title, and interest in and to any Anonymized End User Data effective at the time of the creation of such Anonymized
Data and otherwise the earliest legally recognized and enforceable point in time if different, and all rights, title, and interest
in and to the Anonymized Data Base and all Proprietary Rights in and to any Anonymized Data and all Proprietary Rights in and
to the Anonymized Database. Licensee shall own during the Term all rights, title, and interest in and to all End User Identifiable
Data and the End User Database, subject to the assignment, transfer, and conveyance and Licensor’s rights thereto under
Section 8.3(b).

 

4.6
Provision of Biosensor Data to Licensee. Licensor shall provide, after receipt of Biosensor Data under an Anonymized Identifier,
certain of such Biosensor Data, as agreed with Licensee.

 

4.7
Provision of all data relating to regulatory approval. Licensee shall provide to Licensor a copy of all data, documents
and material provided to or received from any Regulatory Authority (“Regulatory Data”). Licensee unconditionally and
irrevocable provides a royalty free license to the Licensor to use, modify and exploit the Regulatory Data or incorporate the
Regulatory Data into its own data, documents and material and in relation to which the Licensee will have no Proprietary Rights.

 

5.
Ownership and Reservation of Rights

 

5.1
Reservation of Rights. As between Licensor on the one hand and Licensee and all Licensee Personnel on the other hand, Licensor
solely owns and shall solely retain all rights, title, and interest in and to any and all Biosensor Technology, Anonymized End
User Data, Licensed Material, Licensed Trademarks, all Confidential Information of Licensor, any other Mark and any other Technology
of Licensor or any Affiliate, and all Derivations to or of or from or based on or including any Biosensor Technology, Anonymized
End User Data, Licensed Material, Licensed Trademark, Licensor’s Confidential Information, and/or such other Mark and such
other Technology, and all Proprietary Rights in and to any of the foregoing (including, without limitation, all Biosensor Proprietary
Rights), including, without limitation, all rights and remedies for or against any misappropriation of any of the foregoing Technology
or any infringement or misappropriation of any such Proprietary Right, whether before, on, and/or after the Effective Date (collectively,
“Licensor Property”). All rights in and to any and all Licensor Property are expressly reserved. Licensor does
not, and shall not be deemed or held to make, have made, or have agreed to make, under or in connection with this Agreement or
any performance or activities under or related to this Agreement, any assignment, conveyance, transfer, grant, license (except
solely the License during the Term), or entitlement of any kind of or in or to any right, title, interest, lien, or encumbrance
of any kind in or to or under any Licensor Property. If and to the extent that Licensee or any Licensee Personnel owns, co-owns,
acquires, or is entitled to any right, title, interest, lien, or encumbrance of any kind in or to or covering any Licensor Property,
Licensee hereby irrevocably and unconditionally assigns, transfers, and conveys to Licensor, and Licensee shall cause that any
such Licensee Personnel irrevocably and unconditionally assign, transfer, and convey to Licensor, all of such right, title, interest,
lien, or encumbrance of any kind, all without having any right or claim to any royalty, fee, or other payment or value of any
kind against Licensor or any Affiliate.

 

    	 	10	 

     

    

 

5.2
Improvements. The Licensee agrees that all right, title and interest, including in any Technology or Derivation made by,
or on behalf of, the Licensee in connection with the Biosensor IP will be owned by the Licensor (“Improvement”).
The Licensee agrees to notify the Licensor of each Improvement made by, or on behalf of, the Licensee promptly after it is created.
The Licensee assigns to the Licensor, as a present assignment all future right, title and interest in any intellectual property
rights, including any Proprietary Rights, to each Improvement as soon as those rights are created. The Licensee agrees to sign
all documents and do everything required by the Licensor for the purpose of vesting the intellectual property rights, including
Proprietary Rights, in each Improvement to the Licensor. The Licensor agrees that the Proprietary Rights assigned to it by the
Licensee will form part of the license granted to the Licensee under Section 2.1.

 

5.3
Protection. Subject to Section 5.5, Licensor shall have the sole right to decide whether to, and if so, the right to solely
control over, protecting any of the Biosensor IP, Licensed Trademarks, Licensed Material, and other Licensor Property, including,
without limitation, filing, prosecuting, and/or abandoning any patent application, and obtaining, maintaining, and/or abandoning
any patent, for any Biosensor Technology or other Technology, and filing, prosecuting, and/or abandoning any trademark application,
and obtaining, maintaining, and/or abandoning any trademark, for any Licensed Trademark, Licensed Material, or other Mark, work,
or material, or to otherwise protect any Licensor Property, in and/or outside the Territory. Licensee shall, upon and in accordance
with Licensor’s request, assist Licensee with any such application, registration, patenting, or other protection or procedure.
Subject to Section 5.5, Licensee has no right to, and shall not: (i) file or prosecute, any patent application, seek or obtain
any patent, for or including any Biosensor IP; (ii) file or prosecute any application, or seek or obtain any registration, for
any other Licensor Property; (iii) adopt or use as part of its Mark, or apply for, seek, or obtain a registration in the Territory
or anywhere else in the world of or for, (aa) any Licensed Trademark or (bb) any other Mark of Licensor or (cc) any Affiliate
or any Mark similar to a Licensed Trademark or such other Mark, or (did) any translation or transliteration of any of the foregoing
(all except solely if and to the extent such right is granted expressly by Licensor in a written agreement with Licensee); (iv)
claim any ownership or other right, title, or interest in or to, or challenge the ownership or any right of Licensor or any Affiliate
in or to, or challenge the validity or enforceability of, any Licensor Property; and (v) cause, induce, or permit any third party
to do, or assist any third party with doing, any of the foregoing, whether for the benefit of Licensee, such third party, and/or
any other third party.

 

5.4
Infringement and Enforcement. Licensee shall give written notice to Licensor of any infringement of any Licensed Right
or misappropriation of any Biosensor Technology if, and promptly after, Licensee receives knowledge or suspicion thereof. Licensee
shall cooperate reasonably with Licensor in preventing and stopping any such infringement or misappropriation. Subject to Section
5.5, Licensee shall not take any action or undertake any enforcement of any Licensor Property against any third party, and shall
not cause, induce, or permit any third party to do, or assist any third party with doing, any of the foregoing, whether for the
benefit of Licensee, such third party, and/or any other third party.

 

5.5
Protection and Enforcement by Licensee. If within ten (10) days of a written request by Licensee to take action (i) to
protect any of the Biosensor IP, Licensed Trademarks, Licensed Material, and other Licensor Property in the Territory, or (ii)
to enforce any of the foregoing Intellectual Property in the Territory, Licensor does not agree in writing to take such action,
or if Licensor does not diligently pursue any such action after so agreeing in writing to take such action, Licensee may, at its
own cost and expense, take any action reasonably necessary to protect any of the foregoing Intellectual Property in the Territory,
including, without limitation, filing, prosecuting, and/or abandoning any patent application, and obtaining, maintaining, and/or
abandoning any patent, for any Biosensor Technology or other Technology, and any filing, prosecuting, and abandoning any trademark
application, and obtaining, maintaining, and abandoning any trademark, for any Licensed Trademark, Licensed Material, or other
Mark, work, or material, or to otherwise protect any Licensor Property, or to enforce any of the foregoing Intellectual Property
in the Territory.

 

5.6
Further Assurances. Licensee shall take, and cause all Licensee Personnel to take, all such actions and execute all such
documents (including, without limitation, sign and execute any assignment, license, waiver, and other document, provide any testimony
and evidence, and give any other assistance) as and when requested by Licensor to give effect to and implement the sole ownership
of Licensor in and to any and all Licensor Property and/or assist Licensor with protecting and enforcing any of the Licensor Property.

 

    	 	11	 

     

    

 

6.
Confidentiality and Non-Disclosure

 

6.1
Confidential Information. The term “Confidential Information” means any data, documentation, material,
and information that is owned by a Party or is disclosed, provided, or made available by a Party (such Party, the “Disclosing
Party”) to, or directly or indirectly obtained from the Disclosing Party by, the other Party (the “Receiving
Party”) under or in connection with this Agreement, other than any data, documentation, material, and information that
is Non-Confidential Information. The term “Non-Confidential Information” means solely such information that,
and to the extent it: (i) was known publicly, or was known by the Receiving Party without obligation of confidentiality or non-disclosure,
at the time such Property was provided, disclosed, or made available or accessible by the Disclosing Party to, or obtained from
the Disclosing Party by, the Receiving Party; or (ii) becomes known publicly thereafter through no action or fault of the Receiving
Party or any of its employees, or (iii) is developed, created, discovered, or authored by the Receiving Party independently from
this Agreement and any performance hereunder and independently from, and without reference to, any Confidential Information or
Technology of the Disclosing Party, or acquired from a third party other than under a confidentiality and non-disclosure obligation;
provided, however, that any and all. Notwithstanding the foregoing, (i) all Anonymized End User Data, and all Biosensor Technology
(except for any part of the Biosensor Technology that is, and after it becomes, Non-Confidential Information), shall be conclusively
deemed to be Confidential Information solely of Licensor, and (ii) all End User Identifiable Data shall be deemed to be Confidential
Information of Licensee during the Term until delivery thereof to Licensor under Section 8.3(b).

 

6.2
Permitted Use. The Receiving Party may use, copy, reproduce, and utilize any Confidential Information that is provided
or made accessible by the Disclosing Party to the Receiving Party as necessary for such Receiving Party to perform any obligations
or other activities of the Receiving Party, and to exercise any right that the Receiving Party is granted or has, in or under
this Agreement (collectively, “Permitted Use”).

 

6.3
Permitted Disclosure. The Receiving Party may disclose or make available any Confidential Information of the Disclosing
Party to any employee or contractor of such Receiving Party (and if the Receiving Party is Licensee, only any Licensee Personnel
with, and to the extent of, a need to know such Confidential Information) solely as necessary for any Permitted Use and if and
while such employee or contractor is subject to confidentiality and non-disclosure obligations (whether pursuant to a written
agreement or written policy) that are no less stringent than those in this Section 6 (such employee or contractor, a “Permitted
Disclosee”).

 

6.4
Prohibitions. Except solely to the extent expressly permitted under Section 6.2 and Section 6.3, the Receiving Party hereby
agrees that it will not, directly or indirectly, use, copy, reproduce, utilize, disclose, provide or reveal to, or permit or give
access to, any third party, or publish, disseminate, or distribute, any Confidential Information of the Disclosing Party, or any
part thereof, in whatever form or format.

 

6.5
Obligations. The Receiving Party shall (a) take the same precautions to protect the confidentiality of the Confidential
Information as it takes for its own Confidential Information, but in no event less than reasonable precautions and (b) cause any
and all Persons to which access to the Confidential Information is given by such Receiving Party to enter into non-disclosure
and confidentially agreements with the same terms set forth herein with regard to such Confidential Information. In the event
that applicable law requires disclosure of any Confidential Information, the disclosure of such Confidential Information shall
be subject to the following provisions of this Section 6.5. If the Receiving Party or any employee, agent or contractor is requested
under, or required by, law to disclose any Confidential Information of the Disclosing Party, the Receiving Party shall provide
the Disclosing Party with prompt notice of such request or requirement and reasonably assist the Disclosing Party with seeking
an appropriate protective order or other remedy as decided by the Disclosing Party. If such protective order or other remedy is
not obtained, or to the extent that the Disclosing Party waives compliance with the terms of this Agreement, the Receiving Party
or any Permitted Disclosee will disclose only such of the Confidential Information it is legally required to disclose and will
use its best efforts to ensure that all Confidential Information so disclosed will be accorded confidential treatment.

 

6.6
This Agreement. This Agreement, and the terms hereof and thereof, shall be deemed to be Confidential Information of Licensor
only, provided that Licensee may disclose and use this Agreement: (i) in connection with receiving legal or financial advice from
a contractor of Licensee that is subject to a confidentiality obligation regarding this Agreement; (ii) any assertion or enforcement
of any right or remedy under or related to this Agreement; or (iii) if and to the extent required by law upon compliance with
Section 6.5.

 

    	 	12	 

     

    

 

6.7 On
Request. On the request of the Disclosing Party, the Receiving Party must: (i) cease all use of the Confidential
Information of the other party; (ii) destroy or delete all records and copies of the Confidential Information in its
possession; (iii) return to the other party all other Confidential Information of the other party in its possession
(including all copies of the same); and (iv) provide to the other party a written certificate confirming compliance with the
requirements of this Section 6.7, provided that each party may retain one copy of the Confidential Information of the other
party to the extent required by law or for use solely in the event of a dispute arising out of this agreement. In complying
with this clause, the Receiving Party shall not be required to destroy any copies of the Confidential Information which are
maintained in electronic form in back-up tapes, servers, or other sources as a result of the Receiving Party’s normal
back-up procedures for electronic data, provided that provided that such copies are: (v) collected under the Receiving
Party’s usual back-up processes; (vi) are not readily accessible by the Receiving Party; and (vii) no attempt is made
to recover such Confidential Information from the back-up tapes, servers or other sources (except for legal or compliance
purposes).

 

7.
Warranties; Liability

 

7.1
Representations and Warranties. Each Party represents and warrants that it has the authority to enter into this Agreement,
it is not a party to any agreement of any kind that will or may prevent Licensee from entering into or performing its obligations
under this Agreement, and the execution, delivery and performance of this Agreement by such Party has been duly and properly authorized
by all necessary corporate actions, and this Agreement constitutes the valid and binding obligation of such Party. In addition,
Licensee warrants and represents that it will engage in any activities under this Agreement in a professional, good and workmanlike
manner in compliance with all applicable law and all good business and medical professional ethics in the Territory, that it will
not, directly or indirectly, claim ownership or co-ownership in or to, or challenge or contest Licensor’s ownership or rights
in or to, or the validity or enforceability of, any Licensor Property, or assist or support any third party making such claim,
challenge, or contest, that it will perform all activities under this Agreement without disclosing, deliberately or inadvertently,
any confidential information of a third party or misappropriating or violating any third party’s property or right. The
Licensor represents and warrants to the Licensee that it is the legal and beneficial owner of all intellectual property rights
in respect of the Licensed Property and the exercise by the Licensee of its rights under this Licence Agreement in respect of
the Licenced Product will not violate any third party’s property or right.

 

7.2
DISCLAIMER. WITH THE SOLE EXCEPTION OF A PARTY’S WARRANTIES EXPRESSLY SET FORTH IN SECTION 7.1, SUCH PARTY DOES NOT
MAKE ANY REPRESENTATION OR WARRANTY OR CONDITION, AND SUCH PARTY HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES AND CONDITIONS
OF ANY KIND, EXPRESS, IMPLIED, AND STATUTORY. LICENSOR EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES AND CONDITIONS
RELATED TO ANY LICENSED PRODUCT, LICENSED TRADEMARK, LICENSED MATERIAL, LICENSED RIGHTS, BIOSENSOR TECHNOLOGY, AND LICENSOR PROPERTY,
INCLUDING, WITHOUT LIMITATION, ALL WARRANTIES AND REPRESENTATIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON- INFRINGEMENT,
TITLE, OR WORKMANSHIP.

 

    	 	13	 

     

    

 

7.3
EXCLUSION AND LIMITATION OF LIABILITY. IN NO EVENT SHALL A PARTY BE LIABLE TO THE OTHER PARTY OR ANYBODY CLAIMING THROUGH
THE OTHER PARTY FOR ANY INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE, SPECIAL, OR LIQUIDATED DAMAGES OR LOSSES, INCLUDING, WITHOUT
LIMITATION, PROPERTY DAMAGE, DEATH, PHYSICAL OR PSYCHOLOGICAL HARM OR INJURY, LOST BUSINESS OR LOST PROFITS, OF ANY KIND UNDER
OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, ANY SUCH DAMAGES THAT ARISE FROM ANY USE OF ANY LICENSED
TECHNOLOGY. IF A PARTY IS LIABLE FOR ANY DIRECT DAMAGES OR LOSSES UNDER THIS AGREEMENT, OR FOR ANY DAMAGES OR LOSSES THAT CANNOT
BE VALIDLY EXCLUDED UNDER THE FOREGOING PROVISION OF THIS SECTION 7.3, THE TOTAL AND AGGREGATE DAMAGES AND LOSSES FOR WHICH SUCH
PARTY IS LIABLE UNDER THIS AGREEMENT SHALL BE LIMITED IN THE AGGREGATE TO THE SUM OF THE ROYALTY PAID BY LICENSEE TO LICENSOR
UNDER THIS AGREEMENT WITHIN TWELVE (12) MONTHS PRIOR TO ASSERTING SUCH CLAIM FOR SUCH DAMAGES AND LOSSES, BUT IN NO EVENT MORE
THAN THE AGGREGATE AND TOTAL OF ALL ROYALTY AMOUNTS PAID BY LICENSEE TO LICENSOR UNDER THIS AGREEMENT. WITHOUT LIMITING THE FOREGOING,
IN NO EVENT SHALL LICENSOR HAVE ANY INDEMNITY, CONTRIBUTION, OR OTHER OBLIGATION OR LIABILITY WITH REGARD TO ANY OBLIGATION OR
LIABILITY OF LICENSEE OR ANY LICENSEE PERSONNEL, REGARDLESS OF THE LEGAL BASIS OF ANY SUCH OBLIGATION OR LIABILITY AND WHETHER
OR NOT LICENSOR HAS BEEN NOTIFIED OF THE RISK THEREOF. NOTWITHSTANDING THE FOREGOING PROVISIONS OF THIS SECTION 7.3, IN NO EVENT
SHALL ANY LIABILITY OR OBLIGATION OF LICENSEE (i) UNDER SECTIONS 4, 5, 6, 7.4, AND/OR 8.3, OR FOR ANY PERFORMANCE, OR FOR ANY
BREACH OF OR DEFAULT UNDER OR NON- PERFORMANCE OF, ANY OBLIGATION OR LIABILITY UNDER SECTIONS 4, 5, 6, 7.4, AND/OR 8.3, OR (ii)
FOR INFRINGEMENT OF ANY PROPRIETARY RIGHT, OR FOR MISAPPROPRIATION OF ANY TECHNOLOGY, OF LICENSOR OR A THIRD PARTY AFFILIATE OF
LICENSOR, OR (iii) TO THE EXTENT LICENSEE’S LIABILITY MAY NOT BE EXCLUDED UNDER APPLICABLE LAW, OR (iv) FOR ANY COMPENSATION
OR OTHER PAYMENT OWED TO LICENSOR UNDER THIS AGREEMENT, BE EXCLUDED OR LIMITED UNDER THIS SECTION 7.3.

 

7.4
Indemnity by Licensee. Licensee hereby agrees to defend, indemnify, and hold harmless Licensor, all Affiliates, and all
officers, directors, employees, and agents of Licensor or any Affiliate (collectively, the “Indemnitees”) from
and against any claim, action, suit, litigation, demand, allegation, arbitration, proceeding, judgment, order, damages, loss,
liability, injury, costs, expenses (including, without limitation, reasonable attorneys’ fees and witness and other defense
costs), settlement, and other payment obligation of any Indemnitee arising from or in connection with or related to: (i) any promotion,
marketing, import, representation, offer, sale, resale, distribution, or supply of any Licensed Product or any Commercial Unit
or violation of this Agreement, (ii) any activities of performance of, or any claims by, or any non- conformance or conduct of,
any Licensee Personnel, (iii) any collection, storage, processing, transmission, disclosure including unauthorized disclosure,
or use of any Anonymized End User Data or any End User Identifiable Data, including any data or security breach or Interference,
or any Database, or any failure to comply with any provision of Section 4 or any applicable law related to any data or information
including, without limitation, any failure to obtain all required consents and approvals for collection, storage, processing,
transmission, disclosure, and use of any Anonymized End User Data or any End User Identifiable Data as provided or contemplated
under this Agreement, (iv) any direct or indirect infringement or violation of any Proprietary Right of any third party resulting
from, in connection with, or related to any activities of Licensee or any Licensee Personnel, and/or (v) any negligence or willful
misconduct or violation of any applicable law of Licensee or any Licensee Personnel (regardless of any contributory or comparative
negligence of any Indemnitee, but not for any damages to the extent resulting from such contributory or comparative negligence
of any Indemnitee).

 

7.5
Savings Clause. Only in the event, and solely to the extent, that any part or provision of the foregoing provisions in
this Section 7 is invalid or unenforceable in any particular state or jurisdiction, such part or provision shall be interpreted
both to be valid and enforceable and to conform to the greatest extent possible to the intent and purpose of such part or provision
as set forth in this Section 7 and this Agreement.

 

7.5A
Indemnity by Licensor. Licensor hereby agrees to defend, indemnify, and hold harmless Licensee, all Affiliates, and all
officers, directors, employees, and agents of Licensee or any Affiliate (collectively, the “Licensee Indemnitees”)
from and against any claim, action, suit, litigation, demand, allegation, arbitration, proceeding, judgment, order, damages, loss,
liability, injury, costs, expenses (including, without limitation, reasonable attorneys’ fees and witness and other defense
costs), settlement, and other payment obligation of any Licensee Indemnitee arising from or in connection with or related to:
(i) any third party claim that the exercise by the Licensee of its rights under this License Agreement in respect of the Licensed
Product is in violation of their property or rights, and (ii) any Licensed Product regulatory or quality recall or any consumer
or user claims or liability in relation to Licensed Product (regardless of any contributory or comparative negligence of any Licensee
Indemnitee, but not for any damages to the extent resulting from such contributory or comparative negligence of any Licensee Indemnitee).

 

    	 	14	 

     

    

 

8.
Term; Termination

 

8.1
Term.

 

This
Agreement shall commence on the Effective Date and continue until terminated in accordance with Section 8.2.

 

8.2
Termination.

 

a.
Licensee may terminate this Agreement by providing Licensor with written notice of termination in the event: (i) of a material
breach of this Agreement by Licensor, which material breach shall be identified in such written notice, and which termination
shall become effective at the end of thirty (30) days of such written notice of termination unless Licensor fully cured such material
breach within such thirty (30) day period; or (ii) that Licensor discontinues its business operations, takes steps to dissolve
or cease to exist, admits its inability to pay its debts as they become due, files or is or becomes subject to a petition in bankruptcy
(or similar reorganization proceeding) or makes a general assignment for the benefit of its creditors, or becomes subject to the
appointment of a receiver. Licensee also may terminate this Agreement at any time after the tenth (10th) anniversary of the Effective
Date by providing Licensor 180 days’ prior written notice.

 

b.
Licensor may terminate this Agreement by providing Licensee with written notice of termination in the event that Licensee discontinues
its business operations in relation to the Licensed Products, or takes steps to dissolve or cease to exist.

 

8.3
Effect of the End of the Term.

 

a.
Upon the termination of this Agreement, Licensee shall, and Licensee shall cause Licensee Personnel to, (i) immediately cease
any promotion, marketing, import, representation, offer, sale, resale, distribution, or supply of any Licensed Product, use of
any Licensed Trademarks and any Licensed Material, and any other licensed activities, (ii) pay all amounts of Compensation owed
and unpaid, (iii) return to Licensor (or, if and to the extent expressly requested by Licensor to Licensee, irretrievably destroy
or dispose of as directed by Licensor) all Licensed Products not sold (provided that Licensee shall deliver any Licensed Product
at that time already sold by Licensee), all Confidential Information of Licensor, all copies of any Licensed Material, and any
other Licensor Property in the direct or indirect possession or control of Licensee or any Licensee Personnel, and (iv) irretrievably
delete any copy or manifestation of any Confidential Information of Licensor and any Licensed Material that may remain in the
possession or control of Licensee or any Licensee Personnel after such return, destruction, or disposal. Upon Licensor’s
request, Licensee shall certify to Licensor Licensee’s full compliance with the terms of this Section 8.3(a).

 

b.
Upon the termination of this Agreement, Licensee shall promptly: (i) transfer to Licensor each Database and the Correlation Database,
together with all passwords and access information thereto, in an unencrypted, readable, and formattable form with all data and
information therein or related thereto (including, without limitation, all End User Identifiable Data), keeping the Anonymized
Database and its data strictly separate from the End User Identifiable Databased and its data, and keeping each Database strictly
separate from the Correlation Database, and (ii) following such successful transfer and receipt by Licensor, following confirmation
thereof by Licensor, irretrievably and finally delete all Anonymized End User Data, all Anonymized Identifiers, all End User Identifiable
Data, and all other data and information related to any End User or Anonymized Identifier, in the possession or under the control
of Licensee or any Licensee Personnel, and (iii) certify to Licensor Licensee’s full compliance with the terms of this Section
8.3(b).

 

c.
Upon the termination of this Agreement in any way, Licensee shall promptly transfer all Regulatory Approvals and any other approvals
applied for or held by the Licensee to Licensor or a third party or third parties identified by Licensor to Licensee, and take
any action necessary to legally effect such transfer, at Licensee’s risk, responsibility, cost, and expense. Licensee may
not transfer, agree to transfer, promise, or be committed in any way to transfer any Regulatory Approval/ and any other approvals
applied for or held by the Licensee to any third party without Licensor’s express prior written consent.

 

    	 	15	 

     

    

 

8.4
Survival. All provisions in Section 3 (with regard to any Compensation owed and unpaid), Section 4.5, Sections 4.1-4.4
and 4.6 (with regard to any performance or non-performance prior to compliance with Section 8.3(b)), Section 5, Section 6 (other
than Sections 6.2 and 6.3), Section 7, Section 8.3, and Section 9, and this Section 8.4, and Section 1 as relating to such surviving
provisions, shall survive the termination, cancellation or expiration of this Agreement.

 

9.
Miscellaneous

 

9.1
Remedies; Injunctive Relief. Licensee recognizes that, in the event of any breach or anticipated breach of any provisions
in Sections 2, 4, 5, 6, and/or 8.3 by Licensee, Licensor’s right to damages may not be sufficient to avoid, prevent, or
compensate Licensor for any harm arising from such breach. Therefore, Licensee expressly agrees that Licensor is entitled to seek
injunctive relief or specific performance, without need or obligation to post any bond, to enforce any right, license, obligation,
agreement, covenant, term and condition in or under Sections 2, 4, 5, 6, and/or 8.3 against Licensee, in addition to any other
rights and remedies available to Licensor, including, without limitation, any damages, all as Licensor elects in its sole discretion.

 

9.2
Relationship of the Parties. The Parties agree that they are independent contractors and will always represent themselves
to any third parties only as an independent contractor. The Parties are not, and nothing in this Agreement shall be interpreted
that the Parties are, partners, joint venturers, co-owners or otherwise participants in a joint or common undertaking. The employees
or agents of one Party are not, and shall not be construed to be, employees or agents of the other Party, and such other Party
shall not be liable for, have any obligations to, and may not be bound by such employees and agents of the first Party.

 

9.3 Compliance
with Law. Each Party shall perform all activities and obligations under or in connection with this Agreement in
accordance with all applicable law. Each Party shall comply with all applicable trade, import and export laws, rules and
regulations with respect to any Licensed Product and Licensed Material and their use or deliverable. If requested by a Party,
the other Party agrees to sign written assurances and other export-related documents as may be required to comply with U.S.
export regulations. In addition, each Party specifically agrees to comply with all applicable anti-corruption law (including,
without limitation, the U.S. Foreign Corrupt Practices Act, as amended from time to time, the Bribery Act 2010 of the United
Kingdom, and any other applicable foreign or domestic anti-bribery and anti-corruption laws and regulations, and any laws
intended to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business
Transactions).

 

9.4
Assignment. Licensee may not transfer this Agreement, or assign any right or delegate any responsibility or obligation
of Licensee under this Agreement, in whole or in part, without the prior written consent of Licensor. Any attempted transfer,
assignment, or delegation by Licensee in contravention of the foregoing shall be null and void. Licensor may transfer this Agreement,
and assign any right and delegate any responsibility or obligation of Licensor, at any time without consent or notice to Licensee.
This Agreement shall be binding upon and inure to the benefit of the permitted successors and assigns of the Parties. Nothing
in this Agreement shall prevent Licensor from, or limit Licensor in, assigning or transferring or granting any right (subject
to Section 2.2) in or to any Licensor Property.

 

9.5
Entire Agreement; Amendment; Waiver. This Agreement constitutes the entire understanding and agreement between the Parties
hereto related to the subject matter hereof. Neither this Agreement nor any term or provision hereof may be waived, changed, discharged
or terminated except by an instrument in writing signed by the person against whom the enforcement of any waiver, change, discharge
or termination is sought. No modification, amendment, supplement to or waiver of any provision of this Agreement will be binding
upon the Parties unless made in a writing identifying the relevant provisions and signed by each Party through its authorized
representative. A failure of either Party to exercise any right provided for herein shall not be deemed to be a waiver of any
right hereunder. An transfer, assignment, or delegation permitted under Section 9.4 shall not constitute any modification, amendment,
variation, or extension under the immediately preceding sentence if this Agreement does not change as a result of such assignment
(other than the identity and contact information of the assignor to the assignee).

 

    	 	16	 

     

    

 

9.6
Governing Law. THE VALIDITY, ENFORCEABILITY, INTERPRETATION, AND PERFORMANCE OF THIS AGREEMENT SHALL BE GOVERNED BY UNITED
STATES FEDERAL LAWS, TO THE EXTENT APPLICABLE, AND THE LAWS OF THE STATE OF NEW YORK, UNITED STATES OF AMERICA, WITHOUT REGARD
OF ANY CONFLICT OF LAWS PROVISION THAT WOULD RESULT IN THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, AND THE TERMS OF
THIS AGREEMENT SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE WITH SUCH LAWS.

 

9.7
Disputes

 

a.
In the event of any controversy or claim arising out of, relating to or in connection with the License, any provision of this
Agreement, or the rights or obligations of the Parties hereunder, the Parties shall try to settle their differences amicably between
themselves. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party,
and within ten (10) days after such notice appropriate representatives of the Parties shall meet for attempted resolution by good
faith negotiations. If such representatives are unable to resolve promptly such disputed matter, it shall be referred to the CEO
(or equivalent) of Licensor and to the CEO (or equivalent) of Licensee, for discussion and resolution. If such personnel are unable
to resolve such dispute within thirty (30) days of initiating such negotiations, unless otherwise agreed by the Parties, such
dispute shall proceed to mediation as provided under Section 9.7(b).

 

b.
If a dispute arises out of or relates to this Agreement, or the breach thereof, and if the dispute cannot be settled through negotiation,
then the Parties agree to try in good faith to settle the dispute by non-binding mediation with a neutral mediator; provided,
however, that, in the case of a legal dispute, if such mediation has not occurred within sixty (60) days after a written
request for mediation by either Party, then either Party may proceed to resolution pursuant to Section 9.7(c). Each Party has
the right to pursue provisional relief from any court, such as attachment, preliminary injunction, replevin, etc. to avoid irreparable
harm, maintain the status quo, or preserve the subject matter of the dispute, even though mediation has not been commenced or
completed.

 

c.
Any dispute of a legal nature arising out of or connected with the interpretation or enforcement of the legal duties, rights and
obligations under this Agreement, including without limitation, its validity, application or termination, that cannot be settled
by negotiation pursuant to Section 9.7(a) or mediation pursuant to Section 9.7(b) shall be referred to and finally resolved by
arbitration by the ICC International Court of Arbitration of the International Chamber of Commerce. The arbitration shall consist
of a single arbitrator mutually agreed by the Parties, or, in the absence of such agreement, the arbitration shall consist of
a panel of three (3) arbitrators who shall arbitrate the dispute, one to be selected by Licensor, one to be selected by Licensee,
and the third to be selected by mutual agreement of the first two (2) arbitrators so selected. Any arbitration shall take place
in Sydney, Australia, and any arbitration proceeding shall be conducted according to the laws selected under Section 9.6. The
Parties shall conduct the arbitration as expeditiously as possible. Within fifteen (15) days after the conclusion of the arbitration
hearing, the arbitrators shall issue a written award and statement of decision describing the essential findings and conclusions
on which the award is based, including the calculation of any damages awarded. The arbitrators shall not be authorized to reform,
modify or materially amend this Agreement or any provision hereof. The arbitrators shall be authorized to grant any temporary,
preliminary or permanent equitable remedy or relief that they determine to be just or equitable and within the scope of this Agreement,
including an injunction or order for specific performance. The award of the arbitrator shall be final and binding and may be enforced
by any court having jurisdiction. The Parties waive any right to appeal the arbitration award, to the extent a right to appeal
may be lawfully waived. Each Party retains the right to seek judicial assistance (i) to compel arbitration; (ii) to obtain interim
measures of protection pending or during arbitration; and (iii) to enforce any decision of the arbitrator, including the final
award.

 

    	 	17	 

     

    

 

d.
Notwithstanding the provisions of Sections 9.7(a) – 9.7(c), (i) Licensor may seek, obtain, and enforce any injunctive relief
(including, without limitation, for preliminary, emergency, temporary, permanent, or final injunction, specific performance, or
other similar relief under any applicable law) pursuant to Section 9.1, for any threatened or commenced infringement of any Proprietary
Right or misappropriation of any Technology, and/or for asserting any ownership in or to any Licensor Property; and (ii) Licensor
may, but shall not obligated to, proceed under Sections 9.7(a) – 9.7(c) with regard to any cross-claim or third-party claim
or other assertion of a claim by Licensor in a third party’s legal proceeding against Licensor, Licensee, or both Parties.
With respect to any of the foregoing in this Section 9.7(d), and with regard to the enforcement of any arbitration award rendered
pursuant to Sections 9.7(a) – 9.7(c), each Party consents and submits to the non- exclusive jurisdiction of, waiving any
objections to personal jurisdiction in, competent state and federal courts in the State of New York, United States of America
for any litigation or proceeding, and to the venue of such litigation or proceeding in New York City (Borough of Manhattan), New
York, United States of America.

 

e.
All proceedings under this Section 9.7 shall be conducted in the English language and all documents exchanged between the Parties
and/or submitted in the context of a proceeding under this Section 9.7 shall be in English or shall be accompanied with a certified
English translation of the original document.

 

9.8
Severability. If any provision of this Agreement is held to be invalid or unenforceable, the meaning of said provision
will be construed, to the extent feasible, so as to render the provision enforceable, and if no feasible interpretation shall
save such provision, it will be severed from the remainder of this Agreement, as appropriate. The remainder of this Agreement
shall remain in full force and effect unless the severed provision is essential and material to the rights or benefits received
by either Party. In such event, the Parties will use their best efforts to negotiate, in good faith, a substitute, valid and enforceable
provision or agreement, which most nearly effects the Parties’ intent in entering into this Agreement, as appropriate.

 

9.9
Notices. All notices, demands, or other communications to be given or delivered to a Party under or by reason of a provision
of this Agreement shall be in writing and shall be deemed to have been given to such Party when: (i) delivered personally to such
Party at, or sent to such Party by reputable express courier service (charges prepaid) to, such Party’s address set forth
in the caption of this Agreement or another address notified hereunder in writing at least thirty (30) days before such notice,
demand, or other communication by such Party to the other Party, addressed to the attention of (a) the CEO (or equivalent) if
notice is to Licensee, or (b) addressed to the attention of CEO (or equivalent) if notice is to Licensor.

 

9.10
Counterparts. This Agreement may be executed in one or more counterparts (any one of which may be by facsimile or PDF),
all of which shall constitute one and the same agreement.

 

9.11
Consent. Any waiver or consent that may be provided by Licensor under this Agreement may be given or not given in Licensor’s
sole discretion having regard to, amongst other things, without limitation, its own business interests.

 

10.
Additional rights in relation to platform technology.

 

10.1
Right of First Refusal. In the event that the Licensor develops intellectual property using a printable organic thin film
transistor for the detection or measurement of indicators other than the Indicators (“New Indicator IP”) and
is seeking to license the use of the New Indicator IP in the Territory, the Licensor must notify the Licensee in writing of the
terms of the proposed New Indicator IP license. The Licensee shall have thirty (30) days from the date of provision by the Licensor
of a license agreement in relation to the New Indicator IP to exercise its right to enter into the license agreement and Licensor
shall negotiate in good faith with Licensee during such 30 day period. In the event that the Licensee does not exercise its rights
under this Section 10 to enter into a license agreement in the Territory in respect of any New Indicator IP, Licensor may license
the New Indicator IP to any party in its discretion, without further reference to the Licensee; provided the economic terms of
such license are no more favorable to such party than the economic terms of the last license agreement offered to Licensee.

 

[Signature
Page Follows]

 

    	 	18	 

     

    

 

IN
WITNESS WHEREOF, each Party has executed this Agreement as of the Effective Date.

 

	LICENSOR:	 	LICENSEE:
	 	 	 
	Life
    Science Biosensor Diagnostics Pty Ltd.	 	Glucose
    Biosensor Sensor Systems (Greater China) Holdings Inc
	 	 	 	 	 
	By:	 	 	By:	
	 	 	 	 	 
	Name:	C
Tsigounis	 	Name:	J
Hurd
	 	 	 	 	 
	Title:	Sole
Director	 	Title:	Director
	 	 	 	 	 
	Date:	3rd
July 2019	 	Date:	3rd
July 2019

 

    	 	19	 

     

    

 

Schedule
1

 

Licensed
Products

 

The
Licensed Product comprises a product using the Organic Thin Film Technology, the Biosensor Technology encompassing but not limited
to:

 

	 	●	a
    biosensor strip for one or more Indicator, including glucose Indicators; and
	 	●	a
    proprietary smartphone application for the purpose reading, storing, analyzing and providing patient support programs for
    any one or more of the Indicators; and/or
	 	●	a
    dedicated sensor strip reading device

 

that
is derived from the Licensed Rights.

 

    	 	Schedule 1 - 1	 

     

    

 

Schedule
2

 

Licensed
Rights

 

As
advised by the Licensor to the Licensee from time to time in writing, but includes the following:

 

	 	1.	The
    invention(s) described in PCT/AU2013/000207 and associated patent applications: Australian provisional patent application
    2012900885; PCT/AU2013/000207; Chinese patent application 201380022888.2; US patent application 14/382927;
	 	 	 
	 	2.	The
    invention(s) described in the publication ‘printable organic thin film transistors for glucose detection incorporating
    ink jet printing of the enzyme recognition element, and the invention(s) described in PCT/AU2016/050555 and associated patent
    applications: PCT/AU2016/050555 and the National Phase applications it will ultimately produce; and
	 	 	 
	 	3.	all
    project intellectual property within the field,

 

and
any other rights in relation to such inventions with respect to existing and future patents (including any divisions, continuations,
continuations in part, renewals, reissues, extensions, supplementary protection certificates, utility models and foreign equivalents)
and rights with respect to existing and future patent applications and patentable inventions in respect of glucose detection.

 

    	 	Schedule 2 - 1	 

     

    

 

Schedule
3

 

Licensed
Trademarks

 

Common
law trade mark ‘Glucose Biosensor’

 

Such
registered marks as advised in writing by the Licensor to the Licensee from time to time

 

    	 	Schedule 3 - 1	 

     

    

 

Schedule
4

 

Royalties

 

1.
For the one year period commencing on the first day of the first fiscal quarter that starts after

the
receipt of all required Regulatory Approvals in China, and for the one year periods commencing on each anniversary of such day
(each, a “Royalty Year”), the Licensee must pay the Licensor the Minimum Royalties (as defined below), in four
equal installments (the “Royalty Installments”) on the first day of each fiscal quarter during such Royalty
Year (each, a “Royalty Quarter”).

 

2.
At the end of each fiscal quarter, the Licensee will calculate the actual royalties that were generated in accordance with section
5 of this Schedule in that fiscal quarter (“Actual Quarterly Royalties”) and submit such calculations to the Licensor
(“Royalty Calculations”). Within 3 days after receiving the Royalty Calculations, the Licensor will either
confirm in writing that it accepts the Royalty Calculations or provide written calculations or other evidence showing any adjustments
it requires the Licensee to make to the Royalty Calculations (“Royalty Amendment Notice”). Within 3
days after receiving the Royalty Amendment Notice, the Licensee must amend the Royalty Calculations to conform with the Royalty
Amendment Notice, unless the calculations in the Royalty Amendment Notice are materially incorrect. If the Licensee, acting reasonably,
forms the opinion that the calculations in the Royalty Amendment Notice are materially incorrect, then the procedure under section
9.7 of the Agreement will apply for the purpose of determining the correct Royalty Calculations.

 

3.
For any fiscal quarter with respect to which a Royalty Installment was paid, if the Actual Quarterly Royalties are greater than
the Royalty Installment (as provided by the Royalty Calculations), the Licensee will pay the Licensor the calculated difference
between the Actual Quarterly Royalties and the Royalty Installment within 30 days after the Royalty Calculations are accepted
by the Licensor or resolved by the parties under section 9.7. For the avoidance of doubt, each Royalty Installment shall act as
the minimum royalty payment, and there will be no adjustment if the Actual Quarterly Royalties are less than the Royalty Installment
for a Royalty Quarter.

 

4.
For any fiscal quarter with respect to which a Royalty Installment was not paid, the Licensee will pay the Licensor the
Actual Quarterly Royalties within 30 days after the Royalty Calculations are accepted by the Licensor or resolved by the
parties under section 9.7.

 

5.
Royalty payments shall be:

 

	 	a.	13%
    based on Net Sales of Commercial Units prior to the latest Expiry Date of the Patents covered by the License, and 3% based
    on Net Sales of Commercial Units after such date; and
	 	 	 
	 	b.	13%
    based on Net Sales of an optional dedicated reading device.

 

6.
No later than 30 days prior to the beginning of each Royalty Year, the parties agree to meet in good faith to determine the expected
market growth in the Territory for the Royalty Year in respect of the traditional addressable blood glucose monitoring market
in the Territory plus the then existing market for the Licensed Product (“Expected Market Growth”). The Expected
Market Growth will be based on ‘off the shelf’ market research as agreed between the parties. If the parties cannot
agree on the Expected Market Growth for any period within 7 days prior to the relevant anniversary of the Effective Date, either
party may commission an independent qualified third party to determine the Expected Market Growth for the period. The parties
agree to share the cost of any such third-party report commissioned. The Expected Market Growth either determined by agreement
between the parties or reported by a commissioned third party will be applied annually at the first day of each Royalty Year.

 

7.
The Licensee must, on the first day of each Royalty Year after the first Royalty Year, submit to the Licensor sales projections
for the quantity of Commercial Units to be sold by the Licensee in that Royalty Year based on the Commercial Units sold during
the prior Royalty Year multiplied by the Expected Market Growth, plus 7% for each Royalty Year through the tenth (10th) Royalty
Year, and calculate the royalties that would be payable in accordance with section 6 of this Schedule (“Yearly Projected
Royalties”). The “Minimum Royalties” for a Royalty Year shall be (i) $12 million for the first Royalty Year
and (ii) the greater of $12 million and the Yearly Project Royalties for each Royalty Year thereafter.

 

    	 	Schedule 4 - 1	 

     

    

 

Schedule
5

 

Requirements

 

Licensee
shall promote, market, manufacture, import, offer, sell, and supply the Licensed Products, and all Commercial Units, in accordance
with all applicable law and the following requirements, or as otherwise advised in writing by the Licensor:

 

	 	1.	All
    Licensed Products and Commercial Units will be manufactured and supplied to each distributor or End User without the supply
    or inclusion of any other product in accordance with: (i) any Regulatory Approvals and laws regulations and by-law of any
    Regulatory Authority; and (ii) any Good Manufacturing Practices;
	 	 	 
	 	2.	All
    Licensed Products must be promoted and offered for use only in accordance with its regulatory approved use in the Territory
    and in accordance with all relevant medical governance regulation;
	 	 	 
	 	3.	Ensure
    that all Licensed Product is packaged in accordance with all regulatory requirements in the Territory including in an accepted
    language in the Territory;
	 	 	 
	 	4.	The
    Licensed Products and Commercial Units must be supplied to distributors or End Users, in accordance with any Regulatory Approvals
    received from Regulatory Authorities. The Licensee must not interfere with, re-arrange, add or subtract from the supplied
    packaging of the Licensed Products and Commercial Units;
	 	 	 
	 	5.	The
    Licensed Products and Commercial Units must be supplied to distributors or End Users in the label and packaging form as approved
    by any Regulatory Authority and may not include any branding of the Licensee or any other third party;
	 	 	 
	 	6.	The
    Licensed Products and Commercial Units must be supplied to each End User in quantities as directed by the Licensor in writing;
	 	 	 
	 	7.	Licensee
    must satisfy all regulatory requirements pertinent to vigilance and risk management of the device as provided by the Regulatory
    Authorities.
	 	 	 
	 	8.	Sufficient
    records must be collated and retained to allow all Licensed Products and Commercial Units to be recalled if required by any
    government agency in the Territory or the Licensor; and
	 	 	 
	 	9.	The
    Licensor must retain samples of each batch of the Licensed Products for a period of 7 years.
	 	 	 
	 	10.	The
    Licensor must, subject to regulatory requirements in the Territory, package all Licensed Product in accordance with the reasonable
    written requirements of the Licensee.
	 	 	 
	 	11.	The
    Licensor must to the best of its abilities supply and fulfill requests for all materials & information within its control
    necessary for the licensee to fulfill its obligations under this agreement.

 

    	 	Schedule 5 - 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}]]